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Abstract 
The neurological influence of ischemic stroke in the initiation and perpetuation of stroke-
induced heart injury (SIHI) has been acknowledged for several years. However, an underlying 
pathophysiological mechanism remains uncertain. Clinically, it is hypothesized that stroke 
involving the insular cortex (IC) initiates SIHI; since the IC controls autonomic regulation of 
cardiovascular function. Yet, given the high prevalence of shared risk factors between ischemic 
stroke and cardiovascular disorders, mechanistic conclusions from clinical studies are largely 
speculative. We therefore sought to establish a novel rodent model of focal insular ischemic 
stroke, used to evaluate potential behavioural and pathological outcomes of SIHI. Focal 
ischemic stroke was induced into the right or left IC of 6-month-old male Wistar rats, through 
stereotaxic injection of endothelin-1 (ET-1). Control groups received an injection of ibotenic 
acid (IA), phosphate-buffered saline (PBS) or no injection (NI). Before euthanasia, rats were 
assessed for autonomic deficits in sensorimotor gating. At 28 days post-injection, rats with left 
IC damage displayed an overall trend of deficiencies in sensorimotor gating; compared to rats 
with right IC damage and PBS/NI control groups. Pathologically, all injured groups (IA/ET-1) 
exhibited a chronic increase in microglia activation, present at the IC and remote white/grey 
matter regions. Furthermore, these groups expressed cardiac fibrosis within the left atrium. 
When correlated, a positive association between microglia activation and cardiac fibrosis was 
observed. With this novel model, we have successfully identified several downstream 
consequences of IC stroke within the brain and heart, affirming the focal contribution of IC 
damage to SIHI. Taken together, these preliminary results provide important insight into 
potential mechanisms of post-stroke cardiac damage, serving as future therapeutic targets for 
SIHI.        
Keywords: ischemic stroke, stroke-induced heart injury, insular cortex, autonomic 
dysfunction, neuroinflammation 
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1.1 The Brain-Heart Connection 
 Acknowledgement and identification of the brain-heart connection was first reported 
in 1942 by Walter B. Cannon, in his paper entitled “Voodoo Death.” Here, Cannon recounted 
early incidents of sudden death from fright, hypothesizing the innate capability of the nervous 
system to injure the heart 1. Since then, numerous neurological disorders have been associated 
with adverse cardiovascular events 2. Among these, stroke stands out; contributing to a high-
frequency of neurocardiac arrhythmias and lesions 3–6. While it has been speculated that insular 
cortex damage, and arising autonomic dysfunction, contribute to this observed brain-heart 
phenomenon 7, little is known about the underlying pathophysiology; making this intricate 
relationship between the brain and heart a clinically relevant topic of interest. 
1.2 Stroke 
1.2.1 Stroke epidemiology and societal implications 
Stroke is a global burden, negatively impacting the health and wellbeing of individuals 
worldwide 8. In industrialized countries like Canada, stroke is the most common cause of 
morbidity and a prominent source of mortality; only second to heart disease 9. As such, 
numerous research efforts have been dedicated to the investigation of stroke occurrence and 
prevention; resulting in the identification of key risk factors. In particular, high blood pressure, 
diabetes, smoking, heart disease and age have all been recognized as major contributors of 
stroke 10–15. While increased knowledge and public awareness of these risk factors have 
produced a recent North American decline in stroke occurrence 16, age remains a dominant and 
uncontrollable risk factor. With the current ageing population, stroke incidence among the 
elderly is expected to rise, significantly increasing stroke-related socioeconomic and healthcare 
demands 9,17. 
1.2.2 Stroke subtypes 
Traditionally, stroke has been generalized into two basic categories: hemorrhagic and 
ischemic. Hemorrhagic strokes are the less frequent subtype, accounting for approximately 10-
15% of all strokes 18. Manifestation of these strokes occur following the rupture of a cranial 
blood vessel, an associated outcome of chronic hypertension 19–21. Consequently, this bleeding 
within the brain increases intracranial pressure, further causing reduced blood flow to 
surrounding tissue; ultimately expanding the region of hemorrhagic brain damage 22. 
3 
 
Ischemic strokes are typically less severe than hemorrhagic strokes, but much more 
common – accounting for approximately 85-90% of all strokes 18. Due to this greater incidence 
of ischemic strokes, our research will specifically study ischemic-induced cardiovascular 
changes, despite a similar prevalence in both subgroups 6. 
Mechanistically, ischemic strokes occur following the occlusion of a cranial blood 
vessel, which inhibits local blood flow 23. Numerous factors can contribute to this physical 
blockade, including narrowing of the vessel wall (as observed in atherosclerosis) or the 
presence of a blood clot 23. In some circumstances, a temporary blockage of short duration can 
occur, generating a transient ischemic attack (TIA) 24. While the accompanying symptoms and 
damage associated with TIAs are minimal, the occurrence of these “mini-strokes” are known 
to increase the risk of a future ischemic episode 24–26. 
1.2.3 Ischemic stroke interventions 
Presently, intravenous administration of recombinant tissue plasminogen activator 
(rtPA) serves as the only viable treatment for acute ischemic stroke 27,28. This protein acts to 
dissolve the intraluminal clotted material, restoring blood flow to the ischemic region 28. 
However, the therapeutic window for this drug is limited, requiring administration within 4.5 
hours of occlusion onset 28,29. According to epidemiological reports, less than 10% of the 
eligible stroke population receives rtPA 30–32; indicating a strong need for alternative stroke 
therapies. 
1.2.4 Pathophysiology of ischemic stroke 
 The pathophysiological response that occurs following ischemic stroke is a complex 
process. Upon vessel occlusion, nutrient transport is obstructed; depleting local brain tissue of 
key metabolites, such as glucose 33–37. Consequently, cells are incapable of producing adenine 
triphosphate (ATP), an energy storage molecule crucial for tissue cell survival 38. In this 
absence of ATP, an ischemic cascade is activated, initiating the response of several cellular 
mechanisms 33–37. 
An initial loss of blood perfusion, and subsequent energy reduction, impairs cellular 
ionic homeostasis 33–37. In a normal functioning neuron, the influx of potassium (K+) ions and 
efflux of sodium (Na+) and/or calcium (Ca2+) ions across the cell membrane is tightly regulated, 
due to a neuron’s vital role in impulse transmission 39. However, in the absence of ATP, this 
4 
 
regulation is inhibited; allowing for the uncontrolled build-up of intracellular Na+ and Ca2+ 33–
37. Compensation for this increase in cellular Na+ stimulates the movement of water (H2O) into 
the cell, causing cytotoxic edema 40,41. This further restricts cerebral blood flow in surrounding 
areas, enlarging the infarct region 40.  
 In response to the overaccumulation of cellular Ca2+, excess glutamate 
neurotransmitters are released at the neuronal synapse and bind to nearby glutamate receptors: 
N-methyl-D-aspartate (NMDA) or α-amino-3-hydroxy-5-methyl-4-proprionate (AMPA) 42,43. 
This further disrupts the ionic balance of neighbouring cells, initiating an excitotoxic cascade 
44. Additionally, this increased presence of cellular Ca2+ activates degradative enzymes and 
reactive oxygen species (ROS) production; damaging key cellular components, like 
mitochondria 33–37. Consequently, injured mitochondria release apoptotic factors 45, further 
contributing to ischemic cell death. 
Irreversible cell death is the end-product of ischemic stroke, beginning to occur within 
minutes of occlusion 33–37. At the site of blockage, blood levels are reduced to approximately 
10% of basal levels, causing severe brain tissue necrosis 46. Over time, this region becomes 
void of glial cells and neurons, resulting in an undesirable loss of brain function 33–37.  
Adjacent to this core region exists a viable brain area comprised of vulnerable, but 
potentially salvageable tissue; referred to as the ischemic penumbra 33. Collateralization of 
vessel circuitry provides alternative sources of blood supply to this ischemic region, recovering 
blood flow to approximately 20-60% of basal levels 46. Due to the redeeming potential of this 
region, the penumbra serves as an optimal target for future stroke interventions. 
1.2.5 Rodent models of ischemic stroke 
Currently, numerous animal models and techniques are available for the experimental 
study of stroke 47–53. However, selection of the appropriate model should be reflective of the 
clinical research question, as origin, location and size can all change outcomes of human 
ischemic stroke 53,54. Rodents particularly function as an advantageous stroke model, due to 
extensive knowledge of their neuroanatomy 55 and similarities with human cranial circulation 
52.   
Traditionally, middle cerebral artery occlusion (MCAO) has served as a popular 
technique for the induction of ischemic injury. In this method, an endovascular monofilament 
is inserted into the cerebral vasculature of the rat, blocking the middle cerebral artery (MCA) 
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bifurcation 56. This ultimately impairs cerebral blood flow, generating rapid ischemia within 
the cortex and subcortical brain regions 56.  
While implementation of MCAO produces a consistent infarct region, resulting damage 
is widespread and severe 56. Alternatively, intracranial injection of the vasoconstrictor 
endothelin-1 (ET-1) has been used to produce a more targeted area of focal ischemia 57–59. 
Following administration, ET-1 binds to endothelin receptors present on the endothelial cells 
of blood vessels, inducing vasoconstriction 58. Based upon previous MRI perfusion studies, 
resulting ischemia lasts for approximately 1 h before reperfusion 57. Unlike MCAO, use of ET-
1 provides versatility of infarct size and location 54,57. However, it is important to note that 
application of this method causes invasive damage unrelated to ischemic stroke. Intracranial 
insertion of the cannula disrupts the skull, blood-brain barrier (BBB) and secondary brain 
regions 47,53,54; which must be taken into account when analyzing results. In the present study, 
neurocardiac influences associated with insular injury will be examined, requiring the 
production of focal damage. For this reason, the ET-1 ischemic stroke model will be used for 
experiments outlined in this thesis.  
1.3 Ischemic Stroke and Neuroinflammation 
Inflammation is a vital mechanism of ischemic injury, largely modulated by microglia 
and astrocytes – immune cells of the central nervous system (CNS) 35–37,53. During ischemia, 
these cells work to retain neuron health and homeostasis, through active participation in tissue 
repair and regeneration. However, not all forms of cerebral inflammation appear to produce 
beneficial effects. Recent literature has identified a co-existing and contradictory influence of 
neuroinflammation, capable of enhancing peri-infarct damage 60.    
 In response to toxic stimuli released by injured neurons during the ischemic cascade, 
resting astrocytes become activated; referred to as astrogliosis 61. During acute recovery, 
astrocytes function to encapsulate the infarcted region within a glial scar (comprised of 
astrocytes and microglia) in an effort to contain and repair the damaged area 61,62. Recent 
reports suggest that astrocytes may also amplify the ischemic inflammatory response through 
the release of pro-inflammatory cytokines, such as tumour necrosis factor alpha (TNFα) and 
interleukin-1 beta (IL-1β) 63, but exact mechanisms remain unclear.      
 Similar to astrocytes, microglia become activated in response to noxious stimuli; 
termed microgliosis 35–37,53. Upon activation, microglia undergo morphological changes, 
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transitioning from a ramified to amoeboid appearance 64. Interestingly, activated microglia can 
exhibit phenotypic and functional variance depending on the nature, strength and duration of 
presenting stimuli 60,64. Currently, two activated microglia subtypes have been identified: M1 
and M2 60. M2 microglia are characteristically involved with anti-inflammatory efforts; 
phagocytosing toxic debris, releasing anti-inflammatory cytokines, such as transforming 
growth factor beta-1 (TGFβ), and promoting neurogenesis 60,65. Often deemed “helpful” 
microglia, this M2 subtype works to minimize ischemic damage 60. Contrarily, M1 microglia, 
frequently referred to as the “harmful” subtype, display an enhanced pro-inflammatory 
response 60. Activation of these microglia results in the release of numerous pro-inflammatory 
compounds, including TNFα, IL-1β, matrix metalloproteinases (MMPs), ROS and nitric oxide 
(NO) 60,65. The particular presence of MMPs results in disruption of the BBB, allowing for the 
infiltration of peripheral leukocytes 64. This ultimately exacerbates local damage, while 
inducing systemic inflammation; contributing to further stimulation of the immune response. 
Occurrence of this systemic response is evident in a stroke patient’s blood sample, displaying 
increased levels of white blood cells and the inflammatory marker, C-reactive protein (CRP) 
37,66. 
In a recent study by Hu and colleagues, expression profiles of M1/M2 polarization post-
ischemic stroke were outlined. Intriguingly, ischemic microglia activation displayed a 
differential shift in subtype expression 67. Soon after ischemic injury, an increased presence of 
M2 microglia was observed 67. However, this M2 appearance remained transient, gradually 
transitioning to M1 phenotypic-dominance at 7 days post-stroke; suggesting a causative role 
of chronic inflammation in ischemic injury expansion 67. 
1.4 Secondary Consequences of Ischemic Stroke 
1.4.1 Ischemic stroke and white matter injury 
 Damaging effects of ischemia on local grey matter remains a primary focus of stroke 
research. Yet, recent clinical imaging studies have reported persistent white matter 
inflammation (WMI) in major fibre tracts following ischemic stroke; with continued presence 
several months into the recovery period 68–71. Alarmingly, this clinical manifestation of white 
matter pathology has been functionally implicated in post-stroke prognosis; associated with 
worse outcomes of prolonged recovery 68,72,73. As such, secondary presentation of ischemic 
WMI should not be ignored.    
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In the healthy brain, white matter fibre tracts serve as an internal communication 
network, transferring information between remote grey matter regions 66. Macroscopically, 
white matter consists of bundled axons, oligodendrocytes and astrocytes 66. Axons serve as the 
central mechanism for action potential conduction, while also playing an important role in 
nutrient/mediator transport between cell soma and synapse 66. Oligodendrocytes are myelin-
producing cells responsible for axonal myelination 66,74; enhancing the accuracy and speed of 
signal conduction 74. Astrocytes act to support oligodendrocyte and axonal health, influencing 
myelination and maintaining homeostatic equilibrium 74. Together, this white matter unit 
functions to orchestrate rapid neuron-neuron communication 66,74. Damage to any component 
will perturb impulse signalling, causing detrimental sensory, motor and/or cognitive disruption 
66,75. 
Similar to grey matter, white matter is critically dependent on a continuous supply of 
oxygen and nutrients 66. However, unlike grey matter, white matter has a small blood supply 
with limited collateral circulation; making it extremely susceptible to the toxic effects caused 
by post-stroke ischemia 66. Additionally, white matter becomes increasingly susceptible to 
ischemia with age 76,77, further stressing the powerful contribution of white matter injury to 
overall ischemic damage. The pathophysiological cascade of white matter injury following 
ischemic stroke is similar to that observed in grey matter. Depletion of local nutrients inhibits 
oligodendrocyte and astrocyte cellular energy production, causing ionic dyshomeostasis 76. 
This increases extracellular glutamate and ATP, leading to excitotoxicity, oxidative stress and 
initiation of the inflammatory response 76. Necrotic death of local oligodendrocytes ultimately 
induces axonal demyelination and damage, impairing signal transduction 34. It is important to 
note that the efficient conduction of an action potential through white matter circuitry requires 
the persistent supply of energy along the entire length of the axon 66. Consequently, local 
reduction of blood flow at the occluded site can destroy the electrophysiological properties of 
an entire axon, initiating delayed anterograde and/or retrograde secondary axonal degeneration 
66,71. 
1.4.2 Ischemic stroke and neurodegeneration 
Acute grey matter damage at the occlusion site, and within peri-infarct regions, is a 
known consequence of ischemic stroke and an intense focus of pre-clinical neuroprotective 
therapies 78,79. However, recent clinical research has described a delayed occurrence of 
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secondary damage in remote brain regions 80–85 at chronic post-stroke timepoints 68,85; 
suggesting the existence of an ongoing or prolonged ischemic pathology. Neurologically, the 
unfavourable manifestation of this remote injury has corresponded with adverse functional 
deficits in ischemic stroke patients 68,72,73, commonly referred to as “diaschisis” 86.  
Experimentally, several animal studies have observed a similar appearance of remote 
neuronal loss post-ischemic stroke 87–91. In particular, chronic pathology after MCAO in the 
rat has consistently displayed secondary thalamic damage 87–90. More recently, Weishaupt and 
colleagues reported ischemic neurodegeneration and neuronal loss within the retrosplenial 
cortex of the rat, at 28 days following bilateral injection of ET-1 into the prefrontal cortex 91; 
further supporting the aforementioned clinical findings.   
Exact mechanisms of this delayed secondary pathology remain largely unknown and 
may vary depending on the affected structures 91. Yet, an intriguing commonality exists 
between all observations of remote neuronal damage: location of the secondary degeneration 
is dependent on anatomical connectivity to the primary infarct 87–91, suggesting a causative role 
of the previously described white matter injury and axonal degeneration 92. Presently, it is 
hypothesized that following ischemic stroke, axonal degeneration of local inhibitory 
GABAergic neurons prompts a loss of disinhibition to distant brain regions 90,92. Inevitably, 
this fosters an excitotoxic response, evoking neuronal cell death in these secondary areas 90,92. 
A corresponding activation of local inflammatory mechanisms, in particular M1 microglia, 
further enhances necrotic damage, contributing to ongoing chronic neurodegeneration 90,92.  
 While the exacerbated presence of secondary inflammation and neurodegeneration is 
not ideal, the delayed nature of its pathology may widen the therapeutic window for stroke 
intervention 91. As such, future use of anti-inflammatory agents post-ischemic stroke could 
serve to minimize associated functional deficits of secondary damage, ultimately improving 
recovery time.  
1.4.3 Ischemic stroke and heart injury 
Adverse consequences of stroke are not limited to the brain. In fact, extensive clinical 
and experimental research has demonstrated that damage incurred by stroke can extend to the 
heart, causing structural and functional impairments 93–102; referred to as stroke-induced heart 
injury (SIHI). Initial reports of SIHI date back to the early 1950s, when Burch and colleagues 
first identified electrocardiogram (ECG) abnormalities in hemorrhagic stroke patients 101. Soon 
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after, Koskelo and colleagues reported post-mortem presentation of subendocardial 
hemorrhages in patients previously displaying stroke-induced ECG changes 100. Further 
supporting these clinical results, Burch and colleagues were first to confirm the histological 
presence of stroke-induced myocardial lesions in a mouse model of hemorrhagic stroke 98. 
Since then, several animal models of hemorrhagic stroke have reproduced similar arrhythmias 
and/or myocardial lesions 95,96,97,99.  
While early research efforts largely concentrated on hemorrhagic SIHI, similar cardiac 
outcomes have been observed in ischemic stroke patients 102–104. As mentioned previously, 
ischemic stroke accounts for roughly 85-90% of all strokes 18, making this specific 
neurocardiac relationship a great concern. Of particular attention, is the observed contribution 
of ischemic stroke to the development of atrial fibrillation (AF) 102. AF is a form of cardiac 
arrythmia known to increase the risk of stroke 5-fold 15. Currently, approximately 25% of 
ischemic stroke patients display post-stroke cardiac episodes of AF 102; and yet, pathological 
underpinnings remain unknown 105. Furthermore, 20-60% of ischemic stroke patients exhibit 
elevated serum cardiac troponin T (cTnT) levels post-stroke, a known biomarker of myocardial 
injury 104. In a recent report by Wrigley and colleagues, this increased presence of cTnT 
appeared to enhance the long-term risk for death after ischemic stroke 104; implying a capable 
manifestation of acute SIHI into chronic, deadly outcomes. 
1.5 Mechanisms of Stroke-Induced Heart Injury 
1.5.1 The autonomic nervous system 
To date, precise mechanisms of SIHI remain unclear, however, longstanding evidence 
suggests a significant role of autonomic dysfunction 93,97. The autonomic nervous system 
(ANS) is a critical component of the peripheral nervous system (PNS), responsible for the 
maintenance of internal homeostasis 106,107. Traditionally, the ANS has been separated into two 
antagonistic divisions: the sympathetic nervous system (SNS) and the parasympathetic nervous 
system (PSNS) 106,107. Together, these two autonomic branches act to unconsciously regulate 
visceral organ function, including cardiac activity 106,107. A dysfunction in one system often 
leads to adverse changes in the other, resulting in undesirable physiological consequences 2. 
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1.5.2 Neural control of cardiovascular function 
Predominant modulation of autonomic cardiovascular function occurs through an 
expansive network of cortical and subcortical brain regions 2,108–111. Together, these areas alter 
sympathetic and parasympathetic outflow, initiating a change in cardiac activity 2. 
Physiologically, the successful mediation of this neural control requires efficient afferent and 
efferent communication between the brain and heart 108.  
Afferent cardiac signal transduction depends on the internal surveillance of 
cardiovascular mechanical and chemical receptors 106,107,112. Upon activation, these sensory 
receptors will excite intrinsic cardiac neurons, initiating signal propagation 106,107,112. Within 
this autonomic circuitry, the brainstem acts as a vital communication link, relaying sensory 
information from the periphery to upper forebrain regions 2,108. As such, the nucleus of the 
solitary tract (NTS), located within the medulla, serves as the first neural synaptic site of 
afferent cardiac signals (Figure 1A) 2,108–110. From here, the signal is relayed to the parabrachial 
nucleus (PbN) of the pons, prior to reaching the forebrain. Afferent projections from the PbN 
directly synapse at the hypothalamus, amygdala, anterior cingulate cortex (ACC) and 
prefrontal cortex (PFC) 108,109; while the ventroposterior thalamus (VPT) serves as an 
additional relay centre between the PbN and insular cortex (Figure 1A) 108. These cortical and 
subcortical regions act as critical integration sites for autonomic cardiovascular function, 
modulating cardiac activity in response to internal conditions 2,106,107,112. 
Efferent alteration of heart function is directly mediated through sympathetic and 
parasympathetic changes 2. Upon receipt of afferent cardiac information, the aforementioned 
forebrain regions will alter efferent autonomic activity 108–110; evoking an increase or decrease 
in cardiovascular function (Figure 1B) 106,107,112. Increased cardiac activity requires enhanced 
sympathetic output from cardiac nerves, initiated through the excitation of presympathetic 
efferent neurons in the rostral ventrolateral medulla (RVLM) 2. Axons of the RVLM synapse 
with preganglionic cholinergic sympathetic neurons in the spinal cord, which in turn, synapse 
with postganglionic noradrenergic sympathetic neurons of cardiac stellate ganglia (Figure 1B) 
2. Excitation of these noradrenergic sympathetic neurons promotes the release of 
norepinephrine (NE), a neurotransmitter capable of interacting with cardiac adrenergic 
receptors; ultimately increasing heart function 106,107,112.  
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Neural control of cardiovascular function. (A) Afferent pathway of autonomic 
cardiovascular regulation. Brainstem cardiovascular sites (NTS/PbN) act as a vital relay centre 
for the transmission of peripheral cardiac sensory information to regulatory forebrain regions 
(PFC/ACC/HTH/AMYG/IC). The VPT serves as an additional autonomic relay centre 
between the PbN and IC (region not shown). (B) Efferent pathway of autonomic cardiovascular 
regulation. Autonomic modulation by PFC/ACC/HTH/AMYG/IC forebrain regions alters 
sympathetic (RVLM) or parasympathetic (DMV/NA) output, generating an overall increase 
(sympathetic) or decrease (parasympathetic) in heart rhythm. ACC = anterior cingulate cortex, 
PFC = prefrontal cortex, VPT = ventroposterior thalamus, IC = insular cortex, HTH = 
hypothalamus, AMYG = amygdala, PbN = parabrachial nucleus, DMV = dorsal motor nucleus 
of the vagus, NA = nucleus ambiguus, NTS = nucleus of the solitary tract, RVLM = rostral 
ventrolateral medulla. Adapted from Tahsili-Fahadan and Geocadin (2017) 2.  
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Not surprisingly, decreased cardiac activity requires enhanced parasympathetic output, 
initiated through the vagus nerve 2. Upon excitation, preganglionic cholinergic 
parasympathetic neurons at the dorsal motor nucleus of the vagus (DMV) and/or nucleus 
ambiguus (NA), both located within the medulla, will synapse with postganglionic cholinergic 
parasympathetic neurons of efferent cardiac ganglia 2; releasing acetylcholine (ACh) (Figure 
1B) 106,107,112. In turn, this parasympathetic neurotransmitter binds to cardiac muscarinic 
receptors, decreasing heart rate 106,107,112. 
1.5.3 Increased sympathetic activity and stroke-induced heart injury 
Early reports of SIHI have identified an accompanying increase in post-stroke 
sympathetic activity 93–97. Yet, it remains unclear whether this enhanced sympathetic tone is a 
direct effect of sympathetic upregulation, or indirect result of parasympathetic downregulation 
104. Regardless, this sympathetic hyperactivation increases NE release 106,107,112, insinuating a 
potential role of NE toxicity in the development of SIHI 2,93.  
Mechanistically, NE stimulates the synthesis of adenylyl cyclase (AC), an important 
regulator of myocardial Ca2+ channels 113. In the presence of AC, Ca2+ channels will open, 
initiating an influx of Ca2+ into local myocardiocytes 113. These elevated levels of Ca2+ enable 
actin and myosin filaments to interact; an action necessary for cardiac muscle contraction 93,113. 
Pathologically, prolonged exposure to NE will sustain channel opening and Ca2+ availability, 
permitting an unnatural period of continuous contraction 93,113. Consequently, myocardiocytes 
will die, leading to irreversible structural cardiac damage and a corresponding alteration in 
cardiac rhythm 2,93. Furthermore, the increased presence of cellular Ca2+ activates degradative 
enzymes capable of injuring the subendocardial conductive network 2. This ultimately impedes 
proper signal transduction, further disrupting normal heart rate and function 2,93. 
1.5.4 Inflammation and stroke-induced heart injury 
Recently, Olshansky hypothesized a regulatory role of the ANS in myocardial cytokine 
production; similar to that observed in the spleen, liver and intestines 114. Referred to as the 
“inflammatory reflex” or “cholinergic anti-inflammatory pathway,” this neural regulation of 
visceral inflammation is controlled by the vagus nerve 115. In short, the presence of peripheral 
cytokines (TNFα, IL-1β) during an immune response will activate parasympathetic nerve 
fibers, stimulating postganglionic release of ACh from visceral organs 106,107,112,114. This ACh 
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can then enter immune cells through the α7nAChR nicotinic receptor, directly inhibiting 
further transcription of proinflammatory cytokines; attenuating the inflammatory response 
116,117. As mentioned previously, sympathetic hyperactivation is a known outcome of stroke 93–
97. Consequently, an associated decrease in parasympathetic tone could abolish beneficial 
effects of the “inflammatory reflex,” perpetuating SIHI through enhanced cardiac and/or 
systemic inflammation 105. 
1.6 The Insular Cortex and Stroke-Induced Heart Injury 
1.6.1 Insular cortex structure and function 
The insular cortex (IC) is a highly-conserved, multimodal brain region, responsible for 
a variety of cognitive functions 118–121. In humans, the IC lies deep within the lateral sulcus, 
beneath the frontal, parietal and temporal lobes 118. Traditionally, the IC has anatomically been 
divided into an anterior and posterior region; with each extremity substantially differing in 
connectivity to other brain structures 122. As such, the IC remains heavily connected to an 
expansive network of cortical and subcortical regions, serving as a vital sensorimotor 
integration hub 118–120,122. To date, the IC has been implicated in an assortment of higher-order 
functional tasks: ranging from sensory processing to representing feelings and emotions, 
autonomic and motor control, risk prediction and decision-making, as well as complex social 
functions – like empathy 118–123.  
Recently, the pathophysiological relationship between IC damage and SIHI has gained 
increased interest. As mentioned previously, the IC exerts autonomic control over 
cardiovascular function, serving as an important forebrain site for the integration and alteration 
of cardiac activity 2,108,109. It is therefore hypothesized that SIHI is a specific consequence of 
insular ischemic stroke, with damage to the IC disrupting autonomic function; resulting in the 
dysregulation of normal cardiac activity 123. 
1.6.2 Clinical evidence of insular ischemic stroke-induced heart injury 
Supporting this hypothesis, various clinical and epidemiological studies have discerned 
an association between IC damage and SIHI 7,124–127. Most recently, Gonzalez Toledo and 
colleagues identified IC damage in 30.4% of ischemic stroke patients exhibiting atypical post-
stroke ECGs; compared to a 7.3% prevalence in patients with normal post-stroke cardiac 
function 7. While these results suggest an increased risk of cardiac dysfunction following 
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insular ischemic stroke 7, it is important to note that preliminary mechanistic conclusions from 
these clinical studies are largely speculative 105. Given the high prevalence of shared risk 
factors between ischemic stroke and cardiovascular disorders, it is clinically challenging in 
these studies to confidently establish the neurological injury as the cause (or consequence) of 
SIHI 2. Moreover, IC proximity to the MCA further complicates the pathophysiological 
interpretation of current clinical findings. In the past, clinical studies of SIHI predominantly 
recruited MCAO patients, due to the high incidence of this ischemic event. However, resulting 
damage in this stroke region extends beyond the IC 56,120; minimizing the specificity of 
observed results. As such, experimental establishment of a focal insular ischemic stroke animal 
model is critical for the elimination of these clinically-inevitable confounding variables. 
1.6.3 Lateralization of insular autonomic function 
Lateralization of insular autonomic function remains a current topic of discussion, 
bound by contradicting clinical results 127–132. While early researchers identified right IC 
control over sympathetic activity 127,131,132, present studies have produced opposing 
observations 128–130. Most recently, Krause and colleagues were able to temporally localize 
autonomic lateralization to the anatomical subdivisions of the IC; discerning a right-sided 
parasympathetic (and left-sided sympathetic) predominance in the posterior IC 130.   
Intriguingly, current clinical reports have correlated right insular ischemic stroke to 
worsened outcomes 125,133,134. As such, it is theorized that ischemic damage to the right IC 
inhibits parasympathetic control, shifting cardiovascular balance towards an increased 
sympathetic tone 105,130; ultimately causing more severe outcomes of SIHI. 
1.6.4 Rodent models of insular ischemic stroke 
In 1989, Cechetto and colleagues were first to examine stroke-induced autonomic and 
myocardial changes using a rodent model of MCAO; identifying an increase in blood pressure, 
NE and myocardial damage 3 h after ischemic stroke 55. Based upon these results, Cechetto 
and colleagues concluded that their acute stroke model successfully mimicked clinical 
observations of post-stroke autonomic dysfunction 55, further using it to examine lateralization 
of IC autonomic control 135. Interestingly, this subsequent study identified the presentation of 
severe sympathetic consequences following right MCAO 135, implying a right-sided 
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parasympathetic dominance of IC lateralization in the rat. Yet, to our knowledge, additional 
experimental studies have not been performed to validate this finding. 
 As mentioned previously, MCAO (within humans and rodents) creates a large infarct 
region, extending beyond the IC 55,56,120. As such, the isolated association of ischemic IC 
damage with SIHI has yet to be confirmed. In 1995, Butcher and Cechetto reproduced similar 
autonomic changes to those observed in their MCAO stroke model, following injection of the 
excitotoxin D,L-homocysteic acid into the rat IC 136. However, while this method produced 
focal IC damage, the injury was not ischemic; limiting translational potential. With recent 
advances in experimental stroke techniques 57–59, ET-1 can be used to establish a more focal, 
and thus applicable, rodent model of insular ischemic stroke; confirming the mechanistic role 
of IC damage in SIHI. 
1.7 The Acoustic Startle Response 
1.7.1 Circuitry of the acoustic startle response 
In animals, including humans, the startle response is an autonomic reflex that serves to 
protect the body 137–139. Following a sudden and intense stimulus, excitation of the startle reflex 
will initiate rapid activation of cranial, facial and skeletal motor neurons; in preparation for 
facilitation of a fight-or-flight reaction 138,139. Initiation of the startle response can be evoked 
through a variety of sensory signals; including acoustic, tactile, visual and vestibular stimuli 
140 – of which the acoustic startle response (ASR) remains the most studied 139. In humans, 
behavioural observations of this ASR are predominantly measured through the eye-blink reflex 
141,142. 
   Mediation of the ASR occurs through a simple neural circuit in the lower brainstem 
139,143,144, consisting of three main synaptic sites: cochlear root neurons (CRNs), the caudal 
pontine reticular nucleus (PnC) and facial motor neurons (Figure 2) 145,146. In response to a 
loud auditory stimulus, spiral ganglion cells of the cochlea will directly stimulate neighbouring 
hair cells, transferring the sensory signal to CRNs of the auditory nerve 145. From here, axons 
of CRNs extend to the brainstem, synapsing with the cochlear nucleus (CN), which in turn, 
synapses with the PnC 146,147. The PnC serves as the indispensable sensorimotor interface of 
the ASR 148–152. Upon receiving direct acoustic input from CN axons, giant neurons of the PnC 
will project onto cranial, facial and skeletal neurons 152,153 to initiate a reflexive motor response 
(Figure 2). 
16 
 
Figure 2. Neural circuitry of the acoustic startle response. In response to a loud auditory 
stimulus, spiral ganglion cells of the cochlea will stimulate cochlear hair cells; transferring the 
sensory signal along the auditory nerve to the cochlear nucleus (CN) of the lower brainstem. 
CN axons provide direct acoustic input to giant neurons of the caudal pontine reticular nucleus 
(PnC). In turn, these giant neurons of the PnC directly synapse onto cranial, facial and skeletal 
motor neurons, to initiate a rapid reflexive response. Adapted from Koch (1999) 139. 
17 
 
1.7.2 Prepulse inhibition of the acoustic startle response 
Enhancement or attenuation of the ASR can be modulated through a variety of 
influences, including habituation 144,154,155, sensitization 144,156,157 and prepulse inhibition (PPI) 
158,159. In recent years, PPI of the ASR has received growing attention; serving as a reliable 
measure of sensorimotor gating 139,160,161. Sensory gating is an autonomic process responsible 
for the filtration of unnecessary or redundant external stimuli 160–162. Proper function of this 
gating system is imperative for efficient cognitive processing, minimizing overstimulation of 
higher cortical brain regions 160,161. 
PPI is the neurological phenomenon in which a weak prestimulus (prepulse) inhibits 
the reaction to a subsequent strong, startling stimulus; attenuating normal ASR amplitude 
(Figure 3A) 145,159. Exact modulatory mechanisms of PPI on the ASR remain unknown 
139,145,163, however, present evidence suggests a direct inhibition of the PnC (Figure 3B) 
148,152,164,165. In response to an acoustic prepulse stimulus, CN axons will directly innervate the 
inferior colliculus (IFC); a midbrain structure vital for acoustic PPI propagation 166–169. From 
here, the sensory signal is relayed to the superior colliculus (SPC) 170, which in turn, synapses 
with the pedunculopontine tegmental nucleus (PPTg) 171–173. Anatomically, the PPTg contains 
a descending cholinergic projection, directly extending to the PnC of the ASR pathway 174–176. 
As such, stimulation of the PPTg initiates the release of ACh, inhibiting PnC excitation (Figure 
3B) 174–176. Interestingly, ACh acts on the PnC through slow-responding muscarinic receptors, 
eliciting a prolonged inhibitory effect 163,167. Consequently, this long-lasting inhibition will 
attenuate any subsequent startle responses occurring within 30-500 ms after prepulse 
administration 163. 
Currently, recognition of autonomic dysfunction within the rat is predominantly 
classified through measurements of heart rate variability (HRV) or nerve discharge, requiring 
the use of invasive experimental procedures 135,136. However, Saitoh and colleagues have 
reported a noradrenergic influence on PPI; observing deficits in sensorimotor gating following 
blockage of this sympathetically-controlled hormonal system 177. As such, PPI of the ASR was 
implemented in this thesis, to serve as an alternate (and less intrusive) behavioural 
measurement of autonomic impairment. 
1.7.3 Rodent models of the acoustic startle response 
Recognition of the ASR in rats was first reported by Prosser and Hunter in 1936, 
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Figure 3. Schematic overview of PPI and associated neural circuitry. (A) Schematic 
representation of PPI. Administration of a weak prestimulus (prepulse) inhibits the reaction to 
a subsequent strong, startling stimulus; attenuating normal ASR amplitude. Adapted from 
Koch and Schnitzler (1997) 145. (B) Neural circuitry of PPI. In response to an acoustic prepulse 
stimulus, cochlear nucleus (CN) axons will directly innervate the inferior colliculus (IFC). The 
sensory signal is then relayed to the superior colliculus (SPC), which in turn, synapses with the 
pedunculopontine tegmental nucleus (PPTg). Stimulation of the PPTg initiates the release of 
acetylcholine, ultimately inhibiting PnC excitation and attenuating the ASR. Adapted from 
Fendt, Li and Yeomans (2001) 163.  
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confirming identical elicitation and ASR patterns in both humans and rats 139,178. Since then, 
the rodent ASR has been extensively studied, in an attempt to better understand human 
mechanisms of sensorimotor integration 139. In small animals, like the rat, measurements of the 
ASR are recorded from a “whole body” reflex; analogous to the “eye-blink” reflex in humans 
141,142,178. The ASR becomes functional immediately after the onset of hearing, at 
approximately postnatal day 12 in rats 179,180. Differences in strain, and individual variability, 
can alter the magnitude of the ASR 181,182. However, this does not change the quality, or pattern, 
of the reflex; simply causing an enhancement or attenuation of startle magnitude 145. As such, 
the ASR in rodents serves as a reliable and robust measurement of sensorimotor integration 
145.  
Similar to the ASR, identical mechanisms of PPI have been observed in humans and 
rats 158,161,183. In both species, the amplitude of PPI remains dependent on the intensity of the 
prepulse stimulus, as well as the time interval between presentation of the prepulse and 
subsequent startle stimulus, referred to as the interstimulus interval (ISI) 163,184,185. It is 
important to note that due to the neural complexity of PPI mediation and modulation, certain 
physiological manipulations may only affect PPI outcomes at a specific prepulse intensity or 
ISI 184. As such, administration of assorted prepulse trials, varying in intensity (75 dB and 85 
dB) and ISI (30 ms and 100 ms), is encouraged when assessing PPI of sensorimotor gating 184. 
1.8 Rationale, Objective and Hypothesis      
The neurological influence of ischemic stroke in the generation of SIHI has been 
acknowledged for several years 2,93. Yet, despite decades of research, the underlying 
pathophysiology of this intricate brain-heart connection remains unknown. Past studies have 
inferred a causative role of autonomic dysfunction in the manifestation of SIHI 93–97. 
Supporting this, recent clinical data has identified an enhanced prevalence of SIHI in patients 
with damage to the IC 7,124–127, a cortical site vital for the autonomic regulation of 
cardiovascular function 2,108,109. Intriguingly, these clinical studies have discerned worse 
prognostic outcomes with right IC damage 125,133,134; implying a lateralization of IC autonomic 
function. However, it is important to note that preliminary mechanistic conclusions from these 
clinical studies are largely speculative 105, given the high prevalence of shared risk factors 
between ischemic stroke and cardiovascular disorders. As such, the establishment of a novel 
focal insular ischemic stroke animal model is crucial to eliminate these clinically-inevitable 
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confounding variables, and affirm current pathophysiological predictions. Furthermore, 
development of this novel rodent model will allow for the implementation of an accompanying, 
non-invasive behaviour test; aimed to evaluate functional post-insular stroke autonomic 
deficits. Successful application of this behavioural test could vitally improve current 
knowledge of IC autonomic lateralization. 
 In 1989, Cechetto and colleagues successfully reproduced clinical outcomes of stroke-
induced autonomic and myocardial damage, using a rat model of MCAO 55. However, use of 
this technique creates a large infarct region, extending beyond the IC 55,56,120. Consequently, 
the isolated association of ischemic IC damage with SIHI has yet to be confirmed. 
Additionally, due to the invasiveness and severity of the procedure 186, this experimental study 
only assessed acute timepoints 55. Therefore, to date, little is known about the long-term 
prognosis and chronic effects of SIHI. Development of a focal insular stroke rodent model will 
confine primary ischemic damage to the IC, and allow for the extended observation of chronic 
pathology.     
 Recently, the contribution of inflammation, both cerebral and systemic, to SIHI has 
gained increased interest 105,187,188. Pathologically, remote regions of neuroinflammation post-
ischemic stroke have negatively corresponded to worse functional outcomes 68,72,73,86. As 
described previously, the IC belongs to an intricate network of cortical and subcortical 
structures, responsible for the regulation of autonomic cardiovascular function 2,108,109,189. As 
such, histological identification of secondary neuroinflammation, in any of these forebrain 
regions, could provide crucial insight into the neural manifestation of SIHI. Systemically, the 
neuroinflammatory activation of M1 microglia has been known to disrupt the BBB, initiating 
a peripheral immune response 64. Intriguingly, Olshansky has hypothesized a parasympathetic 
role in the downregulation of myocardial inflammation 114. A decrease in parasympathetic tone 
following IC damage could abolish beneficial effects of this PSNS regulation; enhancing 
systemic influence on cardiac inflammation, and resulting SIHI 105; a mechanistic pathway yet 
to be examined.   
 The brain-heart connection remains a relevant and fascinating area of research. While 
past clinical, epidemiological and experimental studies have led to the identification and 
classification of this complex phenomenon, questions of mechanistic contribution remain 
unanswered. Successful establishment of a novel focal insular ischemic stroke rodent model 
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will allow for the extensive investigation of downstream behavioural and pathological 
outcomes; enhancing current pathophysiological knowledge of SIHI. 
Hypothesis: SIHI is the consequence of autonomic dysfunction and inflammation, specific to 
insular ischemic stroke.     
Objective: To establish a novel rodent model of focal insular ischemic stroke that can be used 
to evaluate chronic downstream behavioural and pathological outcomes of the brain and heart; 
improving mechanistic knowledge of SIHI. 
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Section 2: METHODS 
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2.1 Animals 
 Experimental animal procedures were performed in accordance with the Canadian 
Council on Animal Care guidelines and approved by the Western University Animal Care 
Committee (Protocol 2016-027; Appendix). Upon arrival, 54 six-month old male Wistar rats 
(Charles River Laboratories, Montreal, QC), weighing 550-750 g, were individually housed at 
Western University’s Animal Care and Veterinary Services on a 12:12 hour light/dark cycle 
alternating at 1 AM/PM. Room temperature was maintained at 22-24°C, and all rats accessed 
food and water ad libitum. Prior to surgical procedures, rats were randomly assigned to 
experimental groups. 
2.2 Rat Models 
2.2.1 Endothelin-1 ischemic model 
ET-1 is a potent vasoconstrictor frequently used in animal models to produce ischemic 
strokes, similar to those observed in humans 57–59,190–192. Focal injection of ET-1 inhibits 
cerebral blood flow to the targeted brain region for approximately 1 h, prior to reperfusion 57. 
To mimic ischemic stroke in our rodent model, human ET-1 (Lot E7764; Sigma-Aldrich, 
Oakville, ON) was dissolved in sterile saline to achieve a final concentration of 20 pmol/µL. 
Aliquots of 10 µL were stored at ‑80°C until required.     
2.2.2 Ibotenic acid neurotoxic model 
Although ET-1 is most representative of focal human ischemic stroke 191, associated 
ischemia can damage all structures located at the injection site; including intersecting white 
matter fibers 190,193. This makes it difficult to conclude whether observed behavioural and 
pathological outcomes are a direct effect of targeted damage, or an indirect effect of unspecific 
white matter injury. To overcome this confounding dilemma, administration of the neurotoxin 
ibotenic acid (IA) was used as a positive control in this study; causing selective neuronal 
damage within the IC 193,194. For this thesis, IA (Lot ab120041; Abcam Inc., Toronto, ON) was 
dissolved in 0.1 M sterile phosphate-buffered saline (PBS) to achieve a final concentration of 
5 µg/µL. Aliquots of 10 µL were stored at -80°C until required. An additional group of saline 
control animals received administration of 0.1 M sterile PBS.      
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2.2.3 Surgical procedures 
Rats were placed in a Harvard anesthesia box (Harvard Apparatus, Holliston, MA) and 
anesthetized with 4% isoflurane (Baxter Corporation, Mississauga, ON) mixed with 2.0 L/min 
of oxygen. Once fully anesthetized, the head of the rat was shaved to expose the scalp. Rats 
were then transferred to a Kopf stereotaxic frame (David Kopf Instruments, Tujunga, CA) to 
secure head position. While under anesthesia, rat body temperature was maintained at 37°C by 
heating pad. Anesthesia was maintained at 2.5% isoflurane for the duration of surgery.  
Prior to incision, the rat’s scalp was sanitized with soap, followed by 70% ethanol and 
iodine; to minimize risk of infection. A skin incision was then made along the scalp, exposing 
the rat skull and bregma. Pre-determined stereotaxic coordinates 195 (in reference to bregma) 
were used to locate the targeted IC brain region (anterior/posterior (AP): -1.00 mm, 
medial/lateral (ML): ±6.50 mm, dorsal/ventral (DV): -7.00 mm) (Figure 4). Upon 
identification, a single burr hole was drilled into the skull to allow for the 1 µL unilateral 
injection of ET-1, IA or PBS into the right (R) or left (L) IC (n=8/experimental group). 
Injections were performed at a rate of 0.2 µL/min using a 32-guage Hamilton syringe 
(Hamilton Company, Reno, NV), followed by an in situ period of 5 min to prevent solution 
backflow. Post-injection, the burr hole was covered with bone wax (Ethicon LLC, Puerto Rico, 
TX) prior to suturing of the incision site. Rats were then administered a 1 mL/kg subcutaneous 
injection of buprenorphine analgesic (Champion Alstoe Inc., Whitby, ON) and a 0.03 mL 
intramuscular injection of Baytril antibiotic (Bayer Inc., Toronto, ON). Following surgery, rats 
were returned to their individual cage and monitored closely until sternal recumbency was 
regained. Rats were then left freely until behaviour testing and euthanasia 28 d post-surgery. 
Experimental groups were balanced during each surgical day to avoid the introduction of day-
specific confounding variables. 
In addition to the aforementioned groups, an additional control group of no injection 
(NI) animals (n=6) were included in this study. Aside from not receiving a burr hole within the 
skull, or intracranial injection, these rats underwent identical surgical procedures, remaining 
under anesthesia for an equivalent amount of time as injection groups. A post-surgery mortality 
rate of 3.8% was observed in PBS-injected control animals (n=2), with a 0% mortality rate 
observed in all other experimental groups.                    
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Figure 4. Schematic representation of targeted insular cortex brain region. (A) Pre-
determined stereotaxic coordinates were used to locate the IC (red star), in reference to bregma 
(blue dot). Upon identification, a single burr hole was drilled into the rat’s skull to allow for 
the 1 µL unilateral injection of ET-1, IA or PBS into (B) the right or left IC (purple region). IC 
= insular cortex 
 
  
IC 
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2.3 Behaviour Testing 
2.3.1 Prepulse inhibition of the acoustic startle response 
 Twenty-eight days post-surgery, rats were subjected to behaviour testing. PPI of the 
ASR was used to assess deficits in sensorimotor gating following IC injury 139,160,161,184. 
Experimental groups were balanced throughout behavioural testing to avoid the introduction 
of day-specific confounding variables. 
 Two days prior to PPI measurement (day 26), rats were randomly assigned to 1 of 4 
startle boxes (Med Associates Inc., St. Albans, VT) and subjected to four acclimation periods 
(2/day) (Figure 5). Rats were placed into the same startle chamber for the duration of their 
behavioural testing to avoid the introduction of instrument-specific confounding variables. 
All rats were held inside the startle chambers using plastic holders. These holders were 
then attached to transducer platforms, which were used to measure motor output; a reliable 
indicator of the ASR 184. During the first three acclimation periods, rats were exposed to 65 dB 
of white background noise for 5 min. For the final acclimation period, rats were subjected to 
65 dB of white background noise for 5 min, followed by 12 acoustic startle stimuli increasing 
in volume by 5 dB intervals (65-120 dB). This measured and accounted for differences in 
individual startle responses between rats, as some naturally startled more or less than others. 
Sensitivity of the transducer platform was then adjusted, based off natural ASR to these 12 
stimuli.    
Following acclimation, rats underwent PPI testing (day 28) comprised of three phases: 
an acclimation phase, habituation phase (Block I) and PPI phase (Block II). During the 
acclimation phase, rats were exposed to 65 dB of white background noise for 5 min. This was 
immediately followed by Block I, in which rats were subjected to 50 identical trials containing 
an acoustic startle stimulus of 120 dB, administered every 20 s for a duration of 20 ms. 
Throughout Block II, rats were exposed to 50 randomized trials of varying prepulse stimuli, 
occurring every 20 s (Table 1). 
 Startle response data was collected and analyzed using Startle Reflex 5.95 software 
(Med Associates Inc., St. Albans, VT). PPI was calculated for each rat as a comparison to their 
individual startle response, using the following formula: 
% PPI = [1 – (PPI-pulse trial amplitude / pulse alone trial amplitude)]*100 
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Figure 5. Experimental timeline. Six-month old male Wistar rats underwent stereotaxic 
surgery to receive a 1 µL unilateral intracranial injection of ET-1 (20 pmol/µL), IA (5 µg/µL) 
or PBS (0.1 M) into the right or left IC. An additional control group of NI rats received identical 
surgical procedures, without reagent injection. At 26 and 27 d post-surgery, rats were subjected 
to four acclimation periods (2/day), in preparation for the PPI behaviour test. At 28 d post-
surgery, rats underwent PPI behaviour testing prior to euthanasia.   
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Table 1. Prepulse and startle stimuli parameters used during Block II of the PPI 
behaviour test. Rats were exposed to 50 randomized trials of varying prepulse intensity and 
interstimulus intervals (ISIs) to examine changes in sensorimotor gating following IC injury. 
 
Number 
of Trials 
Prepulse 
Intensity 
Prepulse 
Duration 
Startle 
Intensity 
Startle 
Duration 
Interstimulus 
Interval 
Trial A 10 - - 120 dB 20 ms - 
Trial B 10 75 dB 4 ms 120 dB 20 ms 30 ms 
Trial C 10 75 dB 4 ms 120 dB 20 ms 100 ms 
Trial D 10 85 dB 4 ms 120 dB 20 ms 30 ms 
Trial E 10 85 dB 4 ms 120 dB 20 ms 100 ms 
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2.4 Euthanasia   
Immediately following behaviour testing (day 28), rats were euthanized via 2.5 mL 
intraperitoneal injection of pentobarbital (48 mg/mL; Bimeda-MTC, Cambridge, ON). Rats 
were transcardially perfused with 200 mL of 0.01 M PBS (pH 7.35), followed by 300 mL of 
4% paraformaldehyde (PFA). After perfusion, brain and heart tissue were extracted and 
temporarily stored in 4% PFA at 4°C for an additional 24 and 48 h, respectively. Tissue was 
then transferred to 30% sucrose and stored at 4°C until sectioned.  
2.5 Brain Histology and Immunohistochemistry 
2.5.1 Tissue sectioning 
 Brain tissue was flash frozen in Tissue-Tek® O.C.T. Compound (Sakura Finetek USA 
Inc., Torrance, CA) and sectioned into 35 µm coronal sections using the CryoStar NX50 
cryostat (Thermo Fisher Scientific, Waltham, MA). Free-floating sections were divided into 6 
series (210 µm serial sections) and stored in cryoprotectant solution at -20°C until stained.    
2.5.2 Thionine histochemistry 
 Brain tissue was histologically stained with thionine to visualize cellular Nissl 
substance and identify local cell death following IC injury 196. Prior to staining, tissue sections 
were washed in 0.01 M PBS (pH 7.35) for 1 h at room temperature to remove residual 
cryoprotectant. Sections were then pre-mounted on VWR VistaVision™ microscope slides 
(VWR International, Radnor, PA) with 0.3% gelatin (Sigma-Aldrich, Oakville, ON) and left 
to air-dry overnight. The next day, mounted sections were rehydrated by immersion into 
descending concentrations of ethanol (100%, 95%, 70%, 50%), followed by immersion into 
distilled water (dH2O). Sections were then submerged into 0.5% thionin solution for 35 s, prior 
to dehydration. During dehydration, sections were exposed to a series of ascending ethanol 
concentrations (50%, 70%, 95%, 100%) before cleared in xylene (Caledon Laboratories Ltd., 
Georgetown, ON). Slides were then coverslipped using DePex mounting medium (VWR 
International, Radnor, PA) and stored at room temperature. 
2.5.3 Immunohistochemistry 
Brain tissue was immunohistochemically stained for either (i) activated M1 subtype 
microglia, (ii) astrocytes or (iii) neurons, to assess neuroinflammation (microglia/astrocyte 
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activation) 197–200 and secondary neuronal damage (loss of neurons) 201,202 post-insular injury. 
Activated microglia were identified through detection of the major histocompatibility complex 
II (MHC II) molecule, using an OX-6 primary antibody (Lot 554926; BD Biosciences, 
Mississauga, ON). Reactive astrocytes were identified through detection of the glial fibrillary 
acidic protein (GFAP), using a GFAP primary antibody (Lot G3893; Sigma-Aldrich, Oakville, 
ON). Neurons were identified through detection of the DNA-binding neuronal nuclei (NeuN) 
protein, using a NeuN primary antibody (Lot MAB377; Sigma-Aldrich, Oakville, ON). 
For all three stains, tissue sections were washed in 0.01 M PBS (pH 7.35) for 1 h at 
room temperature to remove residual cryoprotectant. Free-floating sections were then 
incubated in 1% hydrogen peroxide (H2O2) for 10 min prior to blocking in 2% horse serum 
(Lot H0146, Sigma-Aldrich, Oakville, ON) for 1 h at room temperature. Sections were then 
incubated in diluted primary antibody solution (OX-6, GFAP or NeuN) overnight at 4°C (Table 
2). The next day, sections were briefly washed with 0.01 M PBS (pH 7.35) for 15 min prior to 
incubation in diluted (1:500) biotinylated anti-mouse IgG secondary antibody solution (Lot 
31806; Thermo Fisher Scientific, Waltham, MA). Tissue remained in secondary antibody 
solution for 1 h at room temperature. Sections were then incubated in 2% Avidin-Biotin 
Complex (ABC) reagent (Lot PI32020; Thermo Fisher Scientific, Waltham, MA) for 1 h. 
Sections were then stained with 0.05% 3,3’-diaminobenzidine tetrahydrochloride (DAB; 
Sigma-Aldrich, Oakville, ON) diluted in 1% H2O2 for 5 min (OX-6) or 30 s (GFAP; NeuN). 
Sections were mounted onto VWR VistaVision™ microscope slides with 0.3% gelatin and left 
to air-dry overnight. The following day, sections were dehydrated via exposure to ascending 
ethanol concentrations (50%, 70%, 95%, 100%) and cleared in xylene. Slides were then 
coverslipped using DePex mounting medium and stored at room temperature. Each staining 
cohort included tissue representation from all experimental groups to eliminate day-specific 
confounding factors associated with natural variance in staining procedures.          
2.6 Heart Histology 
Heart tissue preparation and analysis was completed with assistance from Dr. Brittany 
Balint (Vulnerable Brain Lab, Schulich School of Medicine & Dentistry, Western University) 
and Caroline O’Neil (Molecular Pathology Facility, Robarts Research Institute, Western 
University).  
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Table 2. Product summary of primary antibodies used for the immunohistochemical 
staining of brain tissue. 
  
Antibody Host Species Dilution Ratio Cellular Target 
 
OX-6 
 
 
Mouse - monoclonal 
 
1:1000 
 
Activated microglia 
 
GFAP 
 
 
Mouse - monoclonal 
 
1:2000 
 
Reactive astrocytes 
 
NeuN 
 
 
Mouse - monoclonal 
 
1:1000 
 
Neurons 
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2.6.1 Tissue sectioning  
 Excess connective tissue was removed from rat hearts, prior to placement into tissue 
cassettes (Thermo Fisher Scientific, Waltham, MA) and dehydration via immersion into 
ascending ethanol concentrations (70%, 95%, 100%). Heart tissue was then cleared in xylene, 
before embedded in 65°C paraffin wax. Hearts were embedded to cassette blocks in their 
anterior anatomical position.   
Prior to sectioning, heart tissue was rehydrated in an ice bath for 15 min. Tissue was 
then sliced into 5 µm coronal sections using the Leica CM350 microtome (Leica Biosystemcs 
Inc., Concord, ON). Ribbons of 5-6 tissue sections were then placed into a warm water bath to 
allow for flattening and separation of tissue. Individual sections were then mounted to 
SuperFrost Plus microscope slides (VWR International, Radnor, PA) and incubated overnight 
at 42°C for optimal adhesion. Slides were stored at -20°C until stained.       
2.6.2 Masson’s trichrome histochemistry 
 Heart tissue was histologically stained with Masson’s trichrome to identify regions of 
collagen deposition post-insular injury, indicating cardiac fibrosis 203,204. Prior to staining, pre-
mounted tissue sections were deparaffinized in xylene for 15 min. Sections were then 
rehydrated by immersion into descending concentrations of ethanol (100%, 95%, 70%), 
followed by immersion into dH2O. Tissue sections were then placed into Bouin’s fixative at 
56°C for 1 h, prior to treatment with Weigert’s hematoxylin for 10 min. Sections were then 
stained with Biebrich scarlet-acid fuchsin solution for 2 min and rinsed using 1% 
phosphotungstic acid. Tissue was then transferred to an Aniline blue dye for 5 min and rinsed 
using 1% acetic acid, prior to dehydration. During dehydration, sections were rapidly exposed 
to a series of ascending ethanol concentrations (95%, 100%) before cleared in xylene. Slides 
were then coverslipped using DePex mounting medium. Heart tissue was stained red, blue and 
purple; representing cardiomyocytes, collagen fibers and nuclei, respectively.   
2.7 Tissue Analysis  
2.7.1 Imaging and quantification 
All stained tissue sections were visualized and imaged using a Nikon Eclipse Ni-E 
upright microscope with Nikon DS Fi2 colour camera and NIS Elements imaging software 
(Version 4.30.02; Nikon Instruments Inc., Melville, NY). The experimenter remained blinded 
33 
 
to all group identities throughout quantification to eliminate bias observations. Brain tissue 
stained with thionine confirmed injury location within the IC and was used to select a staining 
cohort (n=6) for each experimental group, dependent on precision of injury location. One NI 
animal was excluded as an outlier during quantification, due to abnormal amounts of 
neuroinflammation (activated microglia).  
To analyze OX-6 and GFAP-stained brain tissue, four stitched photomicrographs (per 
animal; 10X magnification) of 35 µm coronal sections were imaged for each stain (AP: +2.70 
mm, +1.20 mm, -0.40 mm and -3.30 mm, in reference to bregma). Using ImageJ software 
(Version 1.45; National Institute of Health, Bethesda, MD), % area coverage densitometry 
measurements of OX-6 and GFAP immunoreactivity were quantified for four regions of 
interest (ROI): forceps minor, corpus callosum, internal capsule and ventroposterior (VP) 
thalamus (Figure 6). For forceps minor (AP: +2.70 mm), internal capsule (AP: -3.30 mm) and 
VP thalamus assessment (AP: -3.30 mm), analysis was performed using a single coronal 
section. Furthermore, OX-6 and GFAP immunoreactivity was quantified in both hemispheres; 
comparing regions contralateral and ipsilateral to the injection site. To quantify OX-6 and 
GFAP immunoreactivity within the corpus callosum, % area coverage measurements were 
calculated and averaged for three coronal sections (AP: +1.20 mm, -0.40 mm and -3.30 mm, 
in reference to bregma).       
To analyze NeuN-stained brain tissue, four stitched photomicrographs (per animal; 
10X magnification) of 35 µm coronal sections were imaged (AP: +2.70 mm, +1.60 mm, -2.12 
mm and -3.30 mm, in reference to bregma). Using NIS Elements imaging software, automated 
cell count measurements of NeuN immunoreactivity were performed for five ROIs: PFC (AP: 
+2.70 mm), ACC (AP: +1.60 mm), amygdala (AP: -2.12 mm), hypothalamus (AP: -2.12 mm) 
and VP thalamus (AP: -3.30 mm) (Figure 7). For all five ROIs, NeuN immunoreactivity was 
quantified in both hemispheres of a single coronal section, comparing regions contralateral and 
ipsilateral to the injection site.      
To analyze Masson’s Trichrome-stained heart tissue, eight stitched photomicrographs 
(per animal; 10X magnification) of 5 µm coronal sections were imaged from the left atrium 
(LA). Using ImageJ software, colour deconvolution was performed to isolate blue-stained 
tissue (collagen fibers). Percent area coverage of LA cardiac fibrosis was identified as the 
averaged total fraction of blue-stained tissue present within the eight imaged tissue regions. 
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Figure 6. Schematic representation of brain ROIs selected for OX-6 and GFAP analysis. 
To investigate the presence of neuroinflammation, densitometry measurements of OX-6 or 
GFAP immunoreactivity were performed within the (A) forceps minor, (B1-B3) corpus 
callosum, (C) internal capsule and (D) ventroposterior thalamus. Purple regions represent areas 
of interest. AP = anterior/posterior stereotaxic coordinate (in reference to bregma). 
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Figure 7. Schematic representation of brain ROIs selected for NeuN analysis. To 
investigate the presence of neuronal loss, automated cell count measurements of NeuN 
immunoreactivity were performed within the (A) prefrontal cortex, (B) anterior cingulate 
cortex, (C) amygdala, (D) hypothalamus and (E) ventroposterior thalamus. Purple regions 
represent areas of interest. AP = anterior/posterior stereotaxic coordinate (in reference to 
bregma).  
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2.7.2 Statistical analysis  
Statistical analyses were conducted using GraphPad Prism software (Version 7.0; 
GraphPad Software Inc., La Jolla, CA). Statistical significance of dependent variables was 
assessed through two-way analysis of variance (ANOVA) followed by Tukey’s multiple 
comparison test. Data are presented as mean ± standard error of the mean (SEM), with a 
statistical alpha of 0.05.  
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3.1 Qualitative Confirmation of Targeted Insular Damage 
Initial qualitative analysis of injury location was performed to confirm IC damage. 
Brain tissue was histologically stained with thionine to identify Nissl bodies (Figure 8A,B), 
indicating the presence of healthy cell populations. Due to the rapid recovery rate of ischemic 
injury (induced by ET-1), infarct scars were often difficult to clearly visualize at low 
magnification (2X objective lens). However, use of a 20X objective lens revealed a loss of 
neurons and increased presence of supporting glial cells within the IC of injured groups 
(IA/ET-1), compared to uninjured groups (PBS/NI; Figure 8A,B). Additionally, brain tissue 
was immunohistochemically stained with NeuN (Figure 8C,D) and OX-6 (Figure 8E,F) for 
secondary confirmation of targeted IC damage. Staining of tissue with NeuN was used to 
identify neurons and confirmed neuronal loss within the IC of injured groups (IA/ET-1; Figure 
8C). Tissue stained with OX-6 identified substantial amounts of activated microglia present 
within the IC of injured groups (IA/ET-1; Figure 1E), further confirming local damage.     
3.2 Behavioural Assessment  
3.2.1 Left insular damage corresponds with an observed trend of reduced prepulse inhibition 
In developing this rodent model of focal insular ischemic stroke, it was crucial to 
establish an accompanying behaviour test, capable of identifying autonomic deficits post-
insular injury. More importantly, successful implementation of this test could provide valuable 
insight into the lateralization of IC autonomic function. To identify and evaluate autonomic 
dysfunction, PPI of the ASR was measured 28 d following insular injury; indicating functional 
changes in sensorimotor gating. In the past, blockage of the sympathetically-controlled 
noradrenergic system has corresponded with impaired sensorimotor gating 177. As such, rats 
subjected to IC injury, causing decreased sympathetic outflow, were expected to display a 
reduction in PPI; with damage to the IC disrupting sympathetic control of the noradrenergic 
system, inhibiting normal sensorimotor gating processes.   
Administration of the ASR subjected rats to 40 randomized trials of varying prepulse 
stimuli, changing in stimulus intensity (75 dB or 85 dB) and ISI (30 ms or 100 ms). An 
additional 10 trials presented startle stimuli only, to attain baseline startle responses of each 
rat. Percent PPI was calculated as the startle reduction of this averaged baseline measurement, 
with a higher % PPI representing a greater reduction in startle response. 
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Figure 8. Qualitative confirmation of insular damage. Representative 2X photomicrographs 
of coronal rat brain tissue histologically stained with (A,B) thionine, or 
immunohistochemically stained with (C,D) NeuN or (E,F) OX-6, 28 d following intracranial 
injection of PBS (n=7), IA (n=8), ET-1 (n=8) or NI (n=6) into the right or left insular cortex. 
Outlined areas represent higher-magnified regions (20X) of the insular cortex. At 28 d post-
injection, injured rats displayed neuronal loss (A,C: IA/ET-1) and enhanced microgliosis (A,E: 
IA/ET-1) compared to uninjured groups (A,C,E: PBS; B,D,F: NI), confirming insular damage. 
Scale bar = 500 µm (2X) or 50 µm (20X). IC = insular cortex, PBS = phosphate-buffered 
saline, IA = ibotenic acid, ET-1 = endothelin-1, NI = no injection  
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At 28 d post-insular injury, rats subjected to left IC damage (IA/ET-1) displayed an 
observed trend of deficient sensorimotor gating. Administration of a 75 dB prepulse, with 30 
ms ISI, caused a notable decrease in % PPI of IA-L (60.69% ± 14.05%) and ET1-L (59.58% ± 
10.89%) groups, compared to (i) IA-R (96.24% ± 12.93%) and ET1-R (88.51% ± 13.78%) 
injury groups and (ii) PBS-L (102.31% ± 12.65%) and NI (100.00% ± 6.00%) control groups 
(Figure 9A). However, completion of a two-way ANOVA identified no significant effect of 
injury (F(3,50) = 2.42, p = 0.08) and/or insular damage lateralization (F(1,50) = 2.38, p = 0.13). 
Additional trials consisting of (i) 75 dB prepulse with 100 ms ISI (Figure 9B), (ii) 85 dB 
prepulse with 30 ms ISI (Figure 9C) and (iii) 85 dB prepulse with 100 ms ISI (Figure 9D) 
displayed similar results, demonstrating a minor decrease in % PPI of left injury groups 
(IA/ET-1). However, these observed reductions were not as substantial as the trending deficits 
observed after administration of a 75 dB prepulse with 30 ms ISI (Figure 9A).    
3.3 Analysis of Brain Immunohistochemistry 
3.3.1 Insular damage enhances white matter microgliosis, but not astrogliosis, in the corpus 
callosum 
Neuroinflammation is a known consequence of ischemic stroke, vital for post-ischemic 
tissue repair 35–37,53. However, not all neuroinflammation has been associated with beneficial 
effects. In particular, post-stroke chronic inflammation, of remote grey and white matter 
regions, has been shown to perpetuate secondary neurodegeneration in brain regions 
anatomically connected to the primary ischemic infarct 87–91; worsening prognostic outcomes 
and recovery time 68,72,73. We therefore used our established rodent model of focal insular 
ischemic stroke to identify remote regions of secondary cerebral inflammation that may 
contribute to the functional autonomic deficits observed, both clinically and experimentally, 
post-insular injury. 
 Initial analysis of white matter neuroinflammation was performed in the corpus 
callosum; the largest commissural fibre of the brain. Brain tissue was immunohistochemically 
stained with OX-6 or GFAP to identify activated microglia or reactive astrocytes, respectively, 
as both microgliosis and astrogliosis are known mechanisms of neuroinflammation 35–37,53,61. 
Densitometry measurements of % area coverage were quantified as the averaged total fraction 
of OX-6 or GFAP immunolabelled cells present within the corpus callosum of three coronal 
tissue sections. 
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Figure 9. Left insular damage corresponds with an observed trend of reduced prepulse 
inhibition. Percent PPI of the ASR was measured 28 d following intracranial injection of PBS 
(n=7), IA (n=8), ET-1 (n=8) or NI (n=6) into the right or left insular cortex. Rats were subjected 
to randomized trials of varying prepulse stimuli administered at (A) 75 dB, 30 ms before startle 
stimulus, (B) 75 dB, 100 ms before startle stimulus, (C) 85 dB, 30 ms before startle stimulus 
or (D) 85 dB, 100 ms before startle stimulus. Damage to the left insular cortex notably reduced 
% PPI, particularly during administration of a (A) 75 dB prepulse, 30 ms prior to startle 
stimulus. Data is presented as mean ± SEM and normalized to the NI group. IC = insular cortex, 
PPI = prepulse inhibition, PP = prepulse, ISI = interstimulus interval, NI = no injection, PBS 
= phosphate-buffered saline, IA = ibotenic acid, ET-1 = endothelin-1 
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At 28 d post-insular injury, OX-6 staining for activated microglia presented a 
significant effect of injury (F(3,38) = 12.59, p < 0.01, two-way ANOVA). Left IC damage 
resulted in enhanced corpus callosum microgliosis in rats injected with IA (9.82% ± 2.06%) or 
ET-1 (8.15% ± 2.24%), compared to PBS (3.32% ± 0.54%) and NI (1.41% ± 0.31%) rats 
(Figure 10A-C). Increased corpus callosum microgliosis was also observed following injection 
of IA (9.60% ± 1.71%) or ET-1 (5.71% ± 1.78%) into the right IC (Figure 10A,C), indicating 
no significant effect of insular damage lateralization (F(1,38) = 0.56, p = 0.46, two-way 
ANOVA). Rats subjected to injection of PBS into the right IC also displayed minimal 
microgliosis (2.84% ± 0.47%), similar to the PBS-L group (Figure 10A,C). Upon completion 
of Tukey’s multiple comparison test, a significant difference in corpus callosum microgliosis 
between NI/IA-L (p = 0.01), NI/IA-R (p = 0.01) and PBS-R/IA-R (p = 0.04) groups was 
confirmed (Figure 10C). A significant difference between injured groups (IA/ET-1; p = 0.26) 
or uninjured groups (NI/PBS; p = 0.83) was not observed (Figure 10C). GFAP staining for 
reactive astrocytes indicated no significant differences in corpus callosum astrogliosis between 
experimental groups (F(3,38) = 1.53, p = 0.22, two-way ANOVA), with all groups displaying 
similar measurements of GFAP % area coverage: NI (29.89% ± 2.67%), PBS-L (27.27% ± 
4.38%), PBS-R (24.38% ± 2.59%), IA-L (26.66% ± 1.96%), IA-R (22.57% ± 3.62%), ET1-L 
(23.31% ± 3.50%) and ET1-R (23.61% ± 2.16%) (Figure 11A-C).                
3.3.2 Insular damage does not enhance white matter microgliosis or astrogliosis in the forceps 
minor 
In addition to the corpus callosum, neuroinflammation was analyzed within the forceps 
minor. While the corpus callosum is anatomically proximal to the injured insular site, the 
forceps minor is a distal fibre bundle located anteriorly within the frontal lobe; allowing for 
the assessment of neuroinflammatory spread. Densitometry measurements of % area coverage 
were quantified as the total fraction of OX-6 (microglia) or GFAP (astrocytes) immunolabelled 
cells present within the forceps minor of one coronal tissue section. Comparisons of 
microgliosis or astrogliosis within the contralateral and ipsilateral forceps minor were 
performed to account for unilateral IC damage.  
 At 28 d post-insular injury, OX-6 staining for activated microglia presented no 
significant effect of injury for both left (F(3,38) = 2.65, p = 0.06, two-way ANOVA) and right 
(F(3,38) = 1.65, p = 0.19, two-way ANOVA) experimental groups. Following damage to the left 
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Figure 10. Insular damage significantly increases white matter microgliosis within the 
corpus callosum. Representative 2X photomicrographs of OX-6 immunohistochemical 
stained coronal rat brain tissue, 28 d following intracranial injection of (A) PBS, IA, ET-1 
(n=6/experimental group) or (B) no injection (n=5) into the right or left insular cortex. Outlined 
areas represent higher-magnified regions (20X) of the corpus callosum. (C) Quantitative 
analysis revealed significant increases in microglia activation (% area coverage) within the 
corpus callosum 28 d following insular injury. Data is presented as mean ± SEM. Non-
matching letters indicate significant differences between experimental groups (p < 0.05, two-
way ANOVA followed by Tukey’s multiple comparison test). Scale bar = 500 µm (2X) or 50 
µm (20X). IC = insular cortex, PBS = phosphate-buffered saline, IA = ibotenic acid, ET-1 = 
endothelin-1, NI = no injection  
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Figure 11. Insular damage does not enhance white matter astrogliosis within the corpus 
callosum. Representative 2X photomicrographs of GFAP immunohistochemical stained 
coronal rat brain tissue, 28 d following intracranial injection of (A) PBS, IA, ET-1 
(n=6/experimental group) or (B) no injection (n=5) into the right or left insular cortex. Outlined 
areas represent higher-magnified regions (20X) of the corpus callosum. (C) Quantitative 
analysis revealed no significant differences in corpus callosum astrogliosis (% area coverage) 
between experimental groups. Data is presented as mean ± SEM. Scale bar = 500 µm (2X) or 
50 µm (20X). IC = insular cortex, PBS = phosphate-buffered saline, IA = ibotenic acid, ET-1 
= endothelin-1, NI = no injection  
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or right IC, minimal levels of microgliosis within the ipsilateral forceps minor of IA (IA-L 
3.91% ± 1.33%; IA-R 3.62% ± 1.51%) and ET-1 (ET1-L 2.55% ± 0.79%; ET1-R 2.50% ± 
0.85%) groups were observed, compared to PBS (PBS-L 2.55% ± 0.52%; PBS-R 1.99% ± 
0.50%) and NI (1.19% ± 0.32%) control animals (Figure 12A-D). Furthermore, significant 
differences between microglia activation within the contralateral and ipsilateral forceps minor 
of both left (Figure 12C; F(1,38) = 0.01, p = 0.92, two-way ANOVA) and right (Figure 12D; 
F(1,38) = 0.14, p = 0.71, two-way ANOVA) experimental groups were not observed. 
GFAP staining for reactive astrocytes indicated no significant differences in ipsilateral 
forceps minor astrogliosis within left (F(3,38) = 0.89, p = 0.46, two-way ANOVA) and right 
(F(3,38) = 1.06, p = 0.38, two-way ANOVA) experimental groups, with all groups displaying 
similar measurements of GFAP % area coverage: NI (32.62% ± 7.02%), PBS-L (34.23% ± 
4.42%), PBS-R (31.36% ± 4.66%), IA-L (28.44% ± 3.23%), IA-R (28.00% ± 3.43%), ET1-L 
(33.53% ± 3.60%) and ET1-R (25.52% ± 4.87%) (Figure 13A-D). Similar levels of reactive 
astrocytes were also observed within the contralateral forceps minor, revealing no significant 
differences in astrogliosis between the contralateral and ipsilateral forceps minor for both left 
(Figure 13C; F(1,38) = 1.06, p = 0.31, two-way ANOVA) and right (Figure 13D; F(1,38) = 0.16, 
p = 0.69, two-way ANOVA) experimental groups.  
3.3.3 Insular damage enhances white matter microgliosis, but not astrogliosis, in the 
ipsilateral internal capsule 
Additional neuroinflammatory analysis was performed within the internal capsule, a 
subcortical fibre bundle located posteriorly to the injured IC region. Quantification of 
neuroinflammation within this white matter region was of particular interest, as the internal 
capsule comprises the corticobulbar tract; transferring information between the cortex and 
brainstem. With the brainstem home to numerous autonomic cardiovascular centres 2,108,205, a 
neuroinflammatory response within the internal capsule could provide important insight into 
secondary neurodegeneration of autonomic brainstem structures post-insular ischemic stroke. 
Densitometry measurements of % area coverage were quantified as the total fraction of OX-6 
(microglia) or GFAP (astrocytes) immunolabelled cells present within the internal capsule of 
one coronal tissue section. Comparisons of microgliosis or astrogliosis within the contralateral 
and ipsilateral internal capsule were performed to account for unilateral IC damage.  
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Figure 12. Insular damage does not enhance white matter microgliosis within the forceps 
minor. Representative 2X photomicrographs of OX-6 immunohistochemical stained coronal 
rat brain tissue, 28 d following intracranial injection of (A) PBS, IA, ET-1 (n=6/experimental 
group) or (B) no injection (n=5) into the right or left insular cortex. Outlined areas represent 
higher-magnified regions (20X) of the ipsilateral forceps minor. (C, D) Quantitative analysis 
revealed no significant differences in contralateral and ipsilateral forceps minor microgliosis 
(% area coverage) within, and between, experimental groups. Data is presented as mean ± 
SEM. Scale bar = 500 µm (2X) or 50 µm (20X). IC = insular cortex, PBS = phosphate-buffered 
saline, IA = ibotenic acid, ET-1 = endothelin-1, NI = no injection 
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Figure 13. Insular damage does not enhance white matter astrogliosis within the forceps 
minor. Representative 2X photomicrographs of GFAP immunohistochemical stained coronal 
rat brain tissue, 28 d following intracranial injection of (A) PBS, IA, ET-1 (n=6/experimental 
group) or (B) no injection (n=5) into the right or left insular cortex. Outlined areas represent 
higher-magnified regions (20X) of the ipsilateral forceps minor. (C, D) Quantitative analysis 
revealed no significant differences in contralateral and ipsilateral forceps minor astrogliosis (% 
area coverage) within, and between, experimental groups. Data is presented as mean ± SEM. 
Scale bar = 500 µm (2X) or 50 µm (20X). IC = insular cortex, PBS = phosphate-buffered 
saline, IA = ibotenic acid, ET-1 = endothelin-1, NI = no injection  
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At 28 d post-insular injury, OX-6 staining for activated microglia presented a 
significant effect of injury for both left (F(3,38) = 9.32, p < 0.01, two-way ANOVA) and right 
(F(3,38) = 7.87, p < 0.01, two-way ANOVA) experimental groups. Following damage to the left 
or right IC, enhanced levels of microgliosis within the ipsilateral internal capsule of IA (IA-L 
7.83% ± 1.61%; IA-R 11.55% ± 2.45%) and ET-1 (ET1-L 6.82% ± 1.06%; ET1-R 5.66% ± 
1.61%) groups were observed, compared to PBS (PBS-L 3.61% ± 0.85%; PBS-R 3.75% ± 
1.06%) and NI (2.09% ± 0.46%) control animals (Figure 14A-D). Similar levels of 
microgliosis occurred in the ipsilateral internal capsule of both left and right experimental 
injury groups, indicating no significant effect of insular damage lateralization (F(1,38) = 0.56, p 
= 0.46, two-way ANOVA). Upon completion of Tukey’s multiple comparison test, a 
significant difference in ipsilateral internal capsule microgliosis between NI/IA-L (p < 0.01), 
NI/IA-R (p < 0.01), NI/ET1-L (p = 0.01), PBS-L/IA-L (p = 0.04) and PBS-R/IA-R (p < 0.01) 
groups was confirmed (Figure 14C,D). A significant difference between injured groups 
(IA/ET-1; p = 0.10) or uninjured groups (NI/PBS; p = 0.74) was not observed (Figure 14C,D). 
Furthermore, a significant difference between microglia activation within the ipsilateral and 
contralateral internal capsule was observed for both left (F(1,38) = 9.10, p < 0.01, two-way 
ANOVA) and right (F(1,38) = 6.03, p = 0.02, two-way ANOVA) experimental groups (Figure 
14C,D). While IC damage caused enhanced internal capsule microgliosis both contralaterally 
and ipsilaterally, greater levels of microglia activation were observed within the ipsilateral 
internal capsule of IA-L (ipsilateral = 7.83% ± 1.61%; contralateral = 4.36% ± 1.06%), IA-R 
(ipsilateral = 11.55% ± 2.45%; contralateral = 4.94% ± 1.09%), ET1-L (ipsilateral = 6.82% ± 
1.06%; contralateral = 3.92% ± 0.61%) and ET1-R (ipsilateral = 5.66% ± 1.61%; contralateral 
= 3.80% ± 1.16%) groups (Figure 14C,D). Upon completion of Tukey’s multiple comparison 
test, a significant difference between microgliosis within the contralateral and ipsilateral 
internal capsule of the IA-R group (p = 0.02) was confirmed (Figure 14D).  
GFAP staining for reactive astrocytes indicated no significant differences in ipsilateral 
internal capsule astrogliosis within left (F(3,38) = 1.37, p = 0.27, two-way ANOVA) and right 
(F(3,38) = 0.34, p = 0.80, two-way ANOVA) experimental groups, with all groups displaying 
similar measurements of GFAP % area coverage: NI (29.76% ± 8.26%), PBS-L (29.50% ± 
4.56%), PBS-R (28.59% ± 5.58%), IA-L (24.64% ± 2.15%), IA-R (25.30% ± 2.72%), ET1-L 
(33.53% ± 3.60%) and ET1-R (26.17% ± 5.63%) (Figure 15A-D). Similar levels of reactive 
astrocytes were also observed within the contralateral internal capsule, revealing no significant  
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Figure 14. Insular damage significantly increases white matter microgliosis within the 
ipsilateral internal capsule. Representative 2X photomicrographs of OX-6 
immunohistochemical stained coronal rat brain tissue, 28 d following intracranial injection of 
(A) PBS, IA, ET-1 (n=6/experimental group) or (B) no injection (n=5) into the right or left 
insular cortex. Outlined areas represent higher-magnified regions (20X) of the ipsilateral 
internal capsule. (C, D) Quantitative analysis revealed significant increases in microglia 
activation (% area coverage) within the ipsilateral internal capsule 28 d following insular 
injury. Data is presented as mean ± SEM. Non-matching letters indicate significant differences 
between experimental groups (p < 0.05, two-way ANOVA followed by Tukey’s multiple 
comparison test). Scale bar = 500 µm (2X) or 50 µm (20X). IC = insular cortex, PBS = 
phosphate-buffered saline, IA = ibotenic acid, ET-1 = endothelin-1, NI = no injection 
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Figure 15. Insular damage does not enhance white matter astrogliosis within the internal 
capsule. Representative 2X photomicrographs of GFAP immunohistochemical stained coronal 
rat brain tissue, 28 d following intracranial injection of (A) PBS, IA, ET-1 (n=6/experimental 
group) or (B) no injection (n=5) into the right or left insular cortex. Outlined areas represent 
higher-magnified regions (20X) of the ipsilateral internal capsule. (C, D) Quantitative analysis 
revealed no significant differences in contralateral or ipsilateral internal capsule astrogliosis 
(% area coverage) within, and between, experimental groups. Data is presented as mean ± 
SEM. Scale bar = 500 µm (2X) or 50 µm (20X). IC = insular cortex, PBS = phosphate-buffered 
saline, IA = ibotenic acid, ET-1 = endothelin-1, NI = no injection 
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differences in astrogliosis between the contralateral and ipsilateral internal capsule for both left 
(Figure 8C; F(1,38) = 0.34, p = 0.56, two-way ANOVA) and right (Figure 15D; F(1,38) = 0.06, p 
= 0.81, two-way ANOVA) experimental groups.  
3.3.4 Insular damage enhances grey matter microgliosis, but not astrogliosis, in the ipsilateral 
ventroposterior thalamus 
In addition to the aforementioned white matter regions, secondary neuroinflammation 
within the grey matter was examined. Specifically, the investigation of inflammation within 
the VP thalamus was completed, as this region serves as an important relay centre for the 
transmission of cardiac autonomic information between the brainstem and IC 206,207. 
Densitometry measurements of % area coverage were quantified as the total fraction of OX-6 
(microglia) or GFAP (astrocytes) immunolabelled cells present within the VP thalamus of one 
coronal tissue section. Comparisons of microgliosis or astrogliosis within the contralateral and 
ipsilateral VP thalamus were performed to account for unilateral IC damage.   
At 28 d post-insular injury, OX-6 staining for activated microglia presented a 
significant effect of injury for both left (F(3,38) = 11.17, p < 0.01, two-way ANOVA) and right 
(F(3,38) = 19.41, p < 0.01, two-way ANOVA) experimental groups. Following damage to the 
left or right IC, enhanced levels of microgliosis within the ipsilateral VP thalamus of IA (IA-
L 12.55% ± 2.25%; IA-R 11.62% ± 0.70%) and ET-1 (ET1-L 7.30% ± 1.57%; ET1-R 5.40% 
± 1.66%) groups were observed, compared to PBS (PBS-L 2.80% ± 0.81%; PBS-R 2.44% ± 
0.61%) and NI (1.30% ± 0.44%) control animals (Figure 16A-D). Similar levels of 
microgliosis occurred in the ipsilateral VP thalamus of both left and right injury groups, 
indicating no significant effect of insular damage lateralization (F(1,38) = 0.81, p = 0.38, two-
way ANOVA). Upon completion of Tukey’s multiple comparison test, a significant difference 
in ipsilateral VP thalamus microgliosis between NI/IA-L (p < 0.01), NI/IA-R (p < 0.01), 
NI/ET1-L (p = 0.01), NI/ET1-R (p = 0.01), PBS-L/IA-L (p < 0.01), PBS-R/IA-R (p < 0.01), 
IA-L/ET1-L (p = 0.03) and IA-R/ET1-R (p < 0.01) groups was confirmed (Figure 16C,D). A 
significant difference between uninjured control groups (NI/PBS; p = 0.86) was not observed 
(Figure 16C,D). Furthermore, a significant difference between microglia activation within the 
contralateral and ipsilateral VP thalamus was observed for both left (F(1,38) = 41.47, p < 0.01, 
two-way ANOVA) and right (F(1,38) = 52.65, p < 0.01, two-way ANOVA) experimental groups 
(Figure 16C,D). Damage to the left or right IC enhanced microgliosis within the ipsilateral VP  
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Figure 16. Insular damage significantly increases grey matter microgliosis within the 
ipsilateral ventroposterior thalamus. Representative 2X photomicrographs of OX-6 
immunohistochemical stained coronal rat brain tissue, 28 d following intracranial injection of 
(A) PBS, IA, ET-1 (n=6/experimental group) or (B) no injection (n=5) into the right or left 
insular cortex. Outlined areas represent higher-magnified regions (20X) of the ipsilateral 
ventroposterior thalamus. (C, D) Quantitative analysis revealed significant increases in 
microglia activation (% area coverage) within the ipsilateral ventroposterior thalamus 28 d 
following insular injury. Data is presented as mean ± SEM. Non-matching letters indicate 
significant differences between experimental groups (p < 0.05, two-way ANOVA followed by 
Tukey’s multiple comparison test). Scale bar = 500 µm (2X) or 50 µm (20X). IC = insular 
cortex, PBS = phosphate-buffered saline, IA = ibotenic acid, ET-1 = endothelin-1, NI = no 
injection  
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thalamus, with minimal microglia activation occurring in the contralateral VP thalamus: IA-L 
(ipsilateral = 12.55% ± 2.25%; contralateral = 1.35% ± 0.35%), IA-R (ipsilateral = 11.62% ± 
0.70%; contralateral = 1.50% ± 0.53%), ET1-L (ipsilateral = 7.30% ± 1.57%; contralateral = 
0.75% ± 0.17%) and ET1-R (ipsilateral = 5.40% ± 1.66%; contralateral = 1.13% ± 0.26%) 
(Figure 16C,D). Upon completion of Tukey’s multiple comparison test, a significant difference 
between microgliosis within the contralateral and ipsilateral VP thalamus of IA-L (p < 0.01), 
IA-R (p < 0.01), ET1-L (p < 0.01) and ET1-R (p = 0.01) groups was confirmed (Figure 16C,D).  
GFAP staining for reactive astrocytes indicated no significant differences in ipsilateral 
VP thalamus astrogliosis within left (F(3,38) = 2.20, p = 0.10, two-way ANOVA) and right 
(F(3,38) = 0.72, p = 0.55, two-way ANOVA) experimental groups, with all groups displaying 
similar measurements of GFAP % area coverage: NI (10.42% ± 2.02%), PBS-L (14.79% ± 
2.93%), PBS-R (13.67% ± 3.22%), IA-L (22.42% ± 3.17%), IA-R (14.39% ± 2.48%), ET1-L 
(18.38% ± 3.13%) and ET1-R (16.83% ± 2.12%) (Figure 17A-D). Overall, left and right IC 
damage enhanced astrogliosis within the ipsilateral VP thalamus, when compared to the 
contralateral region (Figure 17C,D). However, significant differences between contralateral 
and ipsilateral astrogliosis were only detected among left experimental injury groups (Figure 
17C; F(1,38) = 12.34, p < 0.01, two-way ANOVA). Upon completion of Tukey’s multiple 
comparison test, no significant differences were confirmed (Figure 17C).  
3.3.5 Insular damage does not generate secondary neuronal loss in remote forebrain regions 
As mentioned previously, chronic inflammation within remote grey and white matter 
regions, post-ischemic injury, has contributed to secondary neurodegeneration in brain regions 
anatomically-connected to the primary ischemic infarct 87–91. We therefore sought to 
investigate the occurrence of neuronal death within the VP thalamus; an identified region in 
our insular ischemic model displaying significant amounts of activated microglia. 
Quantification of neuronal death was also completed for four additional brain regions of IC 
autonomic circuitry: the PFC, ACC, amygdala and hypothalamus. At 28 d post-insular injury, 
secondary neuroinflammation was not observed in these regions. However, neuroinflammatory 
timing and mechanisms can vary depending on the involved structures and their degree of 
axonal connectivity to the primary damaged region 91. It is therefore possible that secondary 
neuroinflammation, and corresponding neurodegeneration, occurred prior to the sacrificed  
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Figure 17. Insular damage does not enhance grey matter astrogliosis within the 
ventroposterior thalamus. Representative 2X photomicrographs of GFAP 
immunohistochemical stained coronal rat brain tissue, 28 d following intracranial injection of 
(A) PBS, IA, ET-1 (n=6/experimental group) or (B) no injection (n=5) into the right or left 
insular cortex. Outlined areas represent higher-magnified regions (20X) of the ipsilateral 
ventroposterior thalamus. (C, D) Quantitative analysis revealed no significant differences in 
contralateral and ipsilateral ventroposterior thalamus astrogliosis (% area coverage) within, 
and between, experimental groups. Data is presented as mean ± SEM. Scale bar = 500 µm (2X) 
or 50 µm (20X). IC = insular cortex, PBS = phosphate-buffered saline, IA = ibotenic acid, ET-
1 = endothelin-1, NI = no injection  
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timepoint of 28 days. Furthermore, with the observed presence of WMI in our model, IC 
connectivity to these regions may be impaired, providing additional justification for the 
analysis of secondary neurodegeneration.  
 To investigate the occurrence of neurodegeneration 28 d following IC injury, brain 
tissue was immunohistochemically stained with NeuN to identify neurons and quantify 
neuronal loss. Automated cell counts of NeuN immunoreactivity were performed to obtain a 
single measurement of NeuN+ cells for each ROI. Comparisons of neurodegeneration within 
the contralateral and ipsilateral area of each ROI were conducted to account for unilateral IC 
damage. 
 At 28 d post-insular injury, evidence of secondary neuronal loss in remote grey matter 
forebrain regions was not observed. Completion of a two-way ANOVA indicated no 
significant effect of left IC injury within the ipsilateral region of all ROIs: PFC (Figure 18A-
C; F(3,38) = 2.49, p = 0.08), ACC (Figure 19A-C; F(3,38) = 0.65, p = 0.59), amygdala (Figure 
20A-C; F(3,38) = 0.19, p = 0.90), hypothalamus (Figure 21A-C; F(3,38) = 0.18, p = 0.91) and VP 
thalamus (Figure 22A-C; F(3,38) = 0.37, p = 0.78). Similar results were obtained upon 
completion of a two-way ANOVA for right experimental groups, with no significant 
differences in total neuron amounts observed within the ipsilateral PFC (Figure 18A,B,D; 
F(3,38) = 0.67, p = 0.58), ACC (Figure 19A,B,D; F(3,38) = 1.13, p = 0.35), amygdala (Figure 
20A,B,D; F(3,38) = 0.38, p = 0.77), hypothalamus (Figure 21A,B,D; F(3,38) = 1.51, p = 0.23) and 
VP thalamus (Figure 22A,B,D; F(3,38) = 2.57, p = 0.78). Additionally, similar measurements of 
neuronal cell counts were observed between the contralateral and ipsilateral PFC (Figure 
18C,D), ACC (Figure 19C,D), amygdala (Figure 20C,D), hypothalamus (Figure 21C,D) and 
VP thalamus (Figure 22C,D) of all experimental groups; insinuating an absence of remote 
neurodegeneration.       
3.4 Analysis of Heart Histology 
3.4.1. Left atrial fibrosis of the heart is observed 28 days following insular injury 
While early rodent models of MCAO have mimicked the clinical appearance of cardiac 
lesions post-ischemic stroke 55,135, specificity of IC damage in relation to SIHI has yet to be 
confirmed. We therefore used our novel rodent model of focal insular ischemic stroke to 
examine, for the first time, the downstream effect of selective IC damage on myocardial health 
and structural integrity. 
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Figure 18. Insular damage does not generate secondary neuronal loss within the 
prefrontal cortex. Representative 2X photomicrographs of NeuN immunohistochemical 
stained coronal rat brain tissue, 28 d following intracranial injection of (A) PBS, IA, ET-1 
(n=6/experimental group) or (B) no injection (n=5) into the right or left insular cortex. Outlined 
areas represent higher-magnified regions (20X) of the ipsilateral prefrontal cortex. (C, D) 
Quantitative analysis revealed no significant differences in prefrontal cortex contralateral and 
ipsilateral neuronal cell numbers within, and between, experimental groups. Cell counts 
represent the number of NeuN+ cells within a 1.50 mm2 region of the prefrontal cortex. Data 
is presented as mean ± SEM. Scale bar = 500 µm (2X) or 50 µm (20X). IC = insular cortex, 
PBS = phosphate-buffered saline, IA = ibotenic acid, ET-1 = endothelin-1, NI = no injection 
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Figure 19. Insular damage does not generate secondary neuronal loss within the anterior 
cingulate cortex. Representative 2X photomicrographs of NeuN immunohistochemical 
stained coronal rat brain tissue, 28 d following intracranial injection of (A) PBS, IA, ET-1 
(n=6/experimental group) or (B) no injection (n=5) into the right or left insular cortex. Outlined 
areas represent higher-magnified regions (20X) of the ipsilateral anterior cingulate cortex. (C, 
D) Quantitative analysis revealed no significant differences in anterior cingulate cortex 
contralateral and ipsilateral neuronal cell numbers within, and between, experimental groups. 
Cell counts represent the number of NeuN+ cells within a 1.04 mm2 region of the anterior 
cingulate cortex. Data is presented as mean ± SEM. Scale bar = 500 µm (2X) or 50 µm (20X). 
IC = insular cortex, PBS = phosphate-buffered saline, IA = ibotenic acid, ET-1 = endothelin-
1, NI = no injection  
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Figure 20. Insular damage does not generate secondary neuronal loss within the 
amygdala. Representative 2X photomicrographs of NeuN immunohistochemical stained 
coronal rat brain tissue, 28 d following intracranial injection of (A) PBS, IA, ET-1 
(n=6/experimental group) or (B) no injection (n=5) into the right or left insular cortex. Outlined 
areas represent higher-magnified regions (20X) of the ipsilateral amygdala. (C, D) Quantitative 
analysis revealed no significant differences in amygdala contralateral and ipsilateral neuronal 
cell numbers within, and between, experimental groups. Cell counts represent the number of 
NeuN+ cells within a 0.58 mm2 region of the amygdala. Data is presented as mean ± SEM. 
Scale bar = 500 µm (2X) or 50 µm (20X). IC = insular cortex, PBS = phosphate-buffered 
saline, IA = ibotenic acid, ET-1 = endothelin-1, NI = no injection 
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Figure 21. Insular damage does not generate secondary neuronal loss within the 
hypothalamus. Representative 2X photomicrographs of NeuN immunohistochemical stained 
coronal rat brain tissue, 28 d following intracranial injection of (A) PBS, IA, ET-1 
(n=6/experimental group) or (B) no injection (n=5) into the right or left insular cortex. Outlined 
areas represent higher-magnified regions (20X) of the ipsilateral hypothalamus. (C, D) 
Quantitative analysis revealed no significant differences in hypothalamus contralateral and 
ipsilateral neuronal cell numbers within, and between, experimental groups. Cell counts 
represent the number of NeuN+ cells within a 0.58 mm2 region of the hypothalamus. Data is 
presented as mean ± SEM. Scale bar = 500 µm (2X) or 50 µm (20X). IC = insular cortex, PBS 
= phosphate-buffered saline, IA = ibotenic acid, ET-1 = endothelin-1, NI = no injection 
  
60 
 
Figure 22. Insular damage does not generate secondary neuronal loss within the 
ventroposterior thalamus. Representative 2X photomicrographs of NeuN 
immunohistochemical stained coronal rat brain tissue, 28 d following intracranial injection of 
(A) PBS, IA, ET-1 (n=6/experimental group) or (B) no injection (n=5) into the right or left 
insular cortex. Outlined areas represent higher-magnified regions (20X) of the ipsilateral 
ventroposterior thalamus. (C, D) Quantitative analysis revealed no significant differences in 
ventroposterior thalamus contralateral and ipsilateral neuronal cell numbers within, and 
between, experimental groups. Cell counts represent the number of NeuN+ cells within a 0.58 
mm2 region of the ventroposterior thalamus. Data is presented as mean ± SEM. Scale bar = 
500 µm (2X) or 50 µm (20X). IC = insular cortex, PBS = phosphate-buffered saline, IA = 
ibotenic acid, ET-1 = endothelin-1, NI = no injection 
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Specifically, cardiac tissue was histologically stained with Masson’s trichrome to 
identify fibrotic regions. Tissue stained blue represented extensive collagen deposition, 
indicating the presence of interstitial fibrosis. For this thesis, fibrosis of the LA was analyzed; 
due to the known contribution of LA dysfunction in AF 208,209, and the high clinical prevalence 
of AF associated with SIHI 102. Percent area coverage of LA cardiac fibrosis was quantified as 
the averaged total fraction of blue-stained tissue present within the LA of eight randomly-
selected coronal tissue sections.  
At 28 d post-insular damage, a significant effect of injury was observed (F(3,38) = 14.53, 
p < 0.01, two-way ANOVA). Left IC damage resulted in enhanced LA fibrosis in IA (6.29% 
± 1.62%) and ET-1 (4.49% ± 1.25%) injury groups, compared to PBS (0.79% ± 0.15%) and 
NI (0.53% ± 0.09%) control animals (Figure 23A-C). Increased LA fibrosis was also observed 
following injection of IA (3.04% ± 0.55%) or ET-1 (5.34% ± 0.86%) into the right IC (Figure 
23A,C), indicating no significant effect of insular damage lateralization (F(1,38) = 0.85, p = 0.36, 
two-way ANOVA). Rats subjected to injection of PBS into the right IC displayed minimal 
fibrotic levels (0.87% ± 0.14%), similar to PBS-L control animals (Figure 23A,C). Upon 
completion of Tukey’s multiple comparison test, a significant difference in LA fibrosis 
between NI/IA-L (p < 0.01), NI/ET1-R (p = 0.01), PBS-L/IA-L (p < 0.01) and PBS-R/ET1-R 
(p = 0.01) groups was confirmed (Figure 23C). A significant difference between injured groups 
(IA/ET-1; p = 0.99) or uninjured groups (NI/PBS; p = 1.00) was not observed (Figure 23C).       
3.5 Correlative Analysis of Microglia Activation and Cardiac Fibrosis 
3.5.1 Increased white and grey matter microglia activation positively correlates with left atrial 
cardiac fibrosis   
Using our novel rodent model of focal insular ischemic stroke, we have identified the 
presence of both (1) secondary white and grey matter microgliosis and (2) LA cardiac fibrosis, 
28 d following IC injury. Interestingly, recent studies have hypothesized a causative role of 
inflammation in the genesis and perpetuation of myocardial fibrotic remodelling 
114,187,188,210,211. We therefore sought to examine the relationship between remote cerebral 
inflammation and cardiac fibrosis; correlating levels of activated microglia within the 
ipsilateral forceps minor, corpus callosum, ipsilateral internal capsule or ipsilateral VP 
thalamus, to LA fibrosis. Only rats subjected to ischemic injury (ET-1) and saline control 
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Figure 23. Left atrial fibrosis of the heart significantly increases following injury to the 
insular cortex. Representative 10X photomicrographs of Masson’s trichrome stained coronal 
heart tissue, 28 d following intracranial injection of (A) PBS, IA, ET-1 (n=6/experimental 
group) or (B) no injection (n=5) into the right or left insular cortex. Tissue stained blue 
identifies collagen, indicating fibrosis. (C) Quantitative analysis revealed significant increases 
in left atrial fibrosis (% area coverage) 28 d following insular injury. Data is presented as mean 
± SEM. Non-matching letters indicate significant differences between experimental groups (p 
< 0.05, two-way ANOVA followed by Tukey’s multiple comparison test). Scale bar = 250 µm. 
IC = insular cortex, PBS = phosphate-buffered saline, IA = ibotenic acid, ET-1 = endothelin-
1, NI = no injection  
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animals (PBS) were included in this correlative analysis.  
 At 28 d post-insular ischemic stroke, increased levels of activated microglia 
significantly correlated with enhanced LA fibrosis in the ipsilateral forceps minor (Figure 24A; 
F(1,18) = 6.06, p = 0.02), corpus callosum (Figure 24B; F(1,18) = 22.91, p < 0.01), ipsilateral 
internal capsule (Figure 24C; F(1,18) = 29.38, p < 0.01) and ipsilateral VP thalamus (Figure 
24D; F(1,18) = 19.40, p < 0.01). While all four regions displayed a strong positive correlation, 
the strongest relationship was observed within brain regions proximal to the infarct site (corpus 
callosum: r = 0.75; internal capsule: r = 0.79 and VP thalamus: r = 0.72); compared to the 
more distal forceps minor (r = 0.50) (Figure 24A-D). Upon observation of this positive 
relationship, linear regression analysis was completed to establish regression lines for each 
data set (Figure 24A-D); identifying the overall influence of microglia activation (variable x) 
on LA fibrosis (variable y). It is important to note that although these results depict a strong 
linear relationship between microgliosis and cardiac fibrosis, the observed association remains 
correlative – not causative. As such, a causative implication of neuroinflammation in SIHI can 
not yet be discerned.    
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Figure 24. Increased white and grey matter microglia activation positively correlates with 
left atrial cardiac fibrosis. Correlative depiction of the significant positive association 
between number of activated microglia within the (A) ipsilateral forceps minor (p = 0.02), (B) 
corpus callosum (p < 0.01), (C) ipsilateral internal capsule (p < 0.01) or (D) ipsilateral 
ventroposterior thalamus (p < 0.01), and extent of left atrial cardiac fibrosis 28 d following 
intracranial injection of PBS (grey dots; n=10) or ET-1 (purple dots; n=10) into the left or right 
insular cortex. Significance analyzed using the simple linear regression model (p < 0.05). 
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Section 4: DISCUSSION 
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4.1 Summary of Key Findings 
 Completion of this thesis was performed with the overall intent of establishing a novel 
experimental model of focal ischemic stroke in the rat IC, used to further elucidate the 
mechanistic relationship between IC ischemia and SIHI. In doing so, we confirmed, for the 
first time, the selective role of IC damage in generating SIHI; reaffirming clinical observations. 
To date, experimental studies of SIHI have exclusively involved animal models of MCAO 
55,135. Yet, due to the invasiveness and severity of this procedure 186, observations of SIHI have 
been limited to acute timepoints 55,135. In the present study, use of ET-1 produced a focal, and 
much less severe, ischemic infarct. As such, we were able to first identify the chronic display 
of stroke-induced cardiac fibrosis. At 28 d following IC damage, regions of secondary 
microgliosis were located within the corpus callosum, ipsilateral internal capsule and 
ipsilateral VP thalamus; a known consequence of ischemic stroke. Due to the recent 
implication of inflammation in the manifestation of myocardial fibrotic remodelling 
114,187,188,210,211, microgliosis in these remote regions was correlated to cardiac fibrosis; 
demonstrating, for the first time, a positive association between these two physiological 
variables. Lastly, development of this rodent model allowed for the implementation of a 
behaviour test, used to indirectly assess autonomic deficits of IC damage. Specifically, PPI of 
the ASR was analyzed, suggesting a lateralizing trend of left IC dominance in sensorimotor 
gating. Overall, with the successful development of this insular stroke model, we have begun 
to unravel several pathophysiological outcomes of SIHI; vitally improving current mechanistic 
knowledge of this complex brain-heart connection.                   
4.2 Endothelin-1 vs. Ibotenic Acid 
ET-1 is a potent vasoconstrictor, used in this study to induce insular ischemic stroke 57–
59,191,192. Historically, ET-1 has been recognized as a translational stroke method, best 
representing human ischemic conditions 191. However, resulting ischemia caused by this 
technique will injure all structures located at the injection site; including intersecting white 
matter fibers 190,193. Mechanistically, this makes it difficult to conclude whether reported 
behavioural and pathological outcomes are a direct effect of the targeted damage, or an indirect 
effect of non-specific white matter injury. To overcome this confounding dilemma, the 
neurotoxin IA was included as an additional positive control, causing selective neuronal death 
within the IC 193,194. IA acts as a glutamate agonist, capable of binding to the NMDA glutamate 
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receptor, an important regulator of Ca2+ transport 212. Upon administration of IA into the IC, 
neuronal membrane NMDA receptors become activated, prompting the influx of  extracellular 
Ca2+ into IC neurons 212,213. Similar to ischemic stroke 44, the intracellular accumulation of Ca2+ 
will evoke an excitotoxic cascade, causing neuronal cell death 212,213. In this study, equivalent 
results were obtained following the injection of IA or ET-1 into the rat IC. We can therefore 
conclude that the acquired behavioural and pathological findings of this thesis are a direct result 
of ischemic IC injury, and corresponding physiological processes – not the unspecific damage 
of a traversing white matter tract.      
4.3 Behavioural Assessment: Prepulse Inhibition of the Acoustic Startle Response 
In creating this rodent model of focal insular ischemic stroke, PPI of the ASR was 
performed as an accompanying behaviour test. Traditionally, PPI has served as a reliable 
measure of sensorimotor gating 139,160,161; an autonomic process responsible for the filtration 
of unnecessary or redundant external stimuli 160–162. To our knowledge, a direct relationship 
between the IC and PPI has not yet been reported. However, due to the known autonomic role 
of sensorimotor gating in the regulation of sensory input filtration 160–162, we used PPI of the 
ASR to indirectly measure autonomic outcomes of IC injury. Physiologically, the successful 
implementation of this behaviour test could provide crucial insight into the lateralization of IC 
autonomic function; a current topic bound by contradicting results.  
In 1992, Hachinski and colleagues identified an increased prevalence of severe 
sympathetic consequences following occlusion of the right MCA in the rat 135, suggesting a 
parasympathetic dominance of right IC function. Corresponding with this right MCA territorial 
damage, was the observed elevation of plasma catecholamines (specifically NE); likely caused 
by sympathetic activation of the noradrenergic system 135. Interestingly, Saitoh and colleagues 
have previously reported a noradrenergic influence on PPI, observing deficits in sensorimotor 
gating following blockage of this hormonal system 177. We therefore expected left IC injury to 
impair PPI, reducing attenuation of the ASR. Theoretically, if the left IC truly embodies a 
sympathetic dominance of autonomic function, resulting damage would disrupt sympathetic 
control and inhibit noradrenergic activation; ultimately impeding normal sensorimotor gating.  
At 28 d following IC injury, damage to the left IC caused a notable trend of reduced 
PPI, compared to right injury groups (IA/ET-1) and control groups (PBS/NI); supporting the 
potential lateralization of IC autonomic function. As part of this behaviour test, rats were 
68 
 
subjected to assorted prepulse trials, varying in intensity (75 dB and 85 dB) and ISI (30 ms and 
100 ms). Mediation of PPI primarily occurs through a fast-acting brainstem circuit 163. 
Although, several studies have also identified the advanced processing of prepulse stimuli at 
the forebrain level; capable of exerting a delayed, downstream modulatory effect on PPI 
139,145,214,215. For this reason, PPI is traditionally measured using two ISIs: one of short duration 
(30 ms) and one of long duration (100 ms), to assess experimental alterations in brainstem or 
forebrain circuitry 184. Intriguingly, while prepulse trials of both ISIs demonstrated a trending 
decrease in PPI for left injury groups (IA/ET-1), observed deficits were most substantial 
following administration of a 75 dB prepulse with 30 ms ISI. As such, our impaired 
observations of PPI are likely the result of autonomic brainstem damage and/or dysfunction, 
caused by the downstream effects of left IC injury. However, before such conclusions can be 
drawn, it is important to recall that PPI of the ASR has traditionally been used to assess deficits 
in sensory processing 160–162. Consequently, this observed trend of reduced PPI following left 
IC damage could very-well be attributed to the impairment of normal sensory gating processes, 
unrelated to autonomic dysfunction – requiring the future implementation of alternative 
metrics capable of directly evaluating autonomic changes post-insular ischemic stroke. 
4.4 Insular Ischemic Stroke and Secondary Neuroinflammation 
4.4.1 White matter inflammation and axonal degeneration 
Following ischemic stroke, clinical imaging studies have identified chronic 
inflammation in major white matter tracts, persisting several months into the recovery period 
68–71. Recently, manifestation of this WMI has been implicated in post-stroke prognosis, 
contributing to worse functional outcomes 68,72,73. Physiologically, white matter is essential for 
proper signal transduction between grey matter regions 66,74. For this transmission to efficiently 
occur, a persistent supply of energy is required along the full axon 66. Consequently, damage 
to one area, which may arise during ischemia, can destroy the electrophysiological properties 
of the entire axon; causing axonal degeneration 66,71. Overtime, propagation of this axonal 
damage will inhibit neuronal communication, resulting in adverse functional deficits 66,68,72,73. 
We therefore sought to identify remote areas of secondary neuroinflammation in our insular 
ischemic stroke rodent model. Observed damage in distal white and grey matter regions could 
provide valuable mechanistic insight into the neural manifestation of autonomic dysfunction, 
and resulting SIHI, following IC ischemia.    
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 As anticipated, remote areas of neuroinflammation were identified 28 d following IC 
damage, appearing in both white and grey matter regions. In particular, enhanced microglia 
activation occurred in the corpus callosum, ipsilateral internal capsule and ipsilateral VP 
thalamus of injured groups (IA/ET-1). While minimal amounts of microgliosis were also 
observed within the forceps minor, a significant difference between experimental groups was 
not identified; likely due to the anatomical distance between its anterior location and our (more 
posterior) IC injection site. In this thesis, neuroinflammation was selected as a primary 
histological correlate, to allow for the broader observation of insular stroke-induced 
pathological changes.  
Mechanistically, WMI does not serve as a direct correlate of axonal degeneration. 
However, past experimental reports have discerned microgliosis as a reputable assay for axonal 
health 65,92,216. Recently, Wang and colleagues positively correlated axonal degeneration to M1 
microglia activation, in the corpus callosum of mice subjected to traumatic brain injury 65. 
Physiologically, this makes sense; considering the degradation of axons, or any cellular 
component, is naturally accompanied by an accumulation of toxic waste, stimulating activation 
of a neuroinflammatory response. Thus, the co-occurrence of both axonal degeneration and 
WMI, post-ischemic stroke, is pathologically plausible. We can therefore infer that our 
observations of corpus callosum and internal capsule microgliosis correspond with the chronic 
degeneration of local axons. This associated white matter injury can disrupt signal 
transduction, ultimately leading to the neurodegeneration of remote grey matter regions 90,92.         
Pathologically, the neurodegenerative presentation of this distal grey matter damage is 
anticipated to elicit a chronic, secondary cascade of remote neuroinflammation. In our current 
rat model, significant amounts of activated microglia were identified within the ipsilateral VP 
thalamus 28 d following IC damage; further supporting our mechanistic speculation of white 
matter axonal degeneration. Intriguingly, the VP thalamus serves as a vital relay centre for the 
transmission of autonomic cardiovascular information between the brainstem and IC 108. As 
such, the downstream manifestation of neurodegeneration within this brain region, likely 
contributes to associated autonomic deficits of SIHI. Additional staining for histological 
markers specific to degeneration, such as Fluoro-Jade B 91,217, should be performed to confirm 
this mechanistic prediction of secondary degeneration.     
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4.4.2 Additional causes of microglia activation  
 In addition to the injured groups (IA/ET-1), basal levels of microgliosis were observed 
in our NI rats; insinuating an innate presence of microgliosis. Often, microglia are exclusively 
viewed as immune cells of the brain. However, these multifunctional cells participate in an 
array of physiological processes, regulating homeostasis and maintaining overall brain health 
218. During the absence of an immune response, microglia will continue to scavenge the CNS: 
phagocytosing aged cells, faulty synapses and/or local waste products 218. Consequently, this 
internal cleanup of cellular debris requires the basal activation of M1 microglia; likely 
contributing to the observed presence of microgliosis within our NI rats. 
4.4.3 Pathological absence of lateralization 
 As discussed earlier, behavioural measurements of PPI displayed recognizable 
differences between left and right insular injury groups, suggesting a lateralization of IC 
autonomic function. Consequently, a pathological lateralization of neuroinflammation, 
corresponding with this behavioural observation, was anticipated. Yet, at 28 d following IC 
damage, similar regions (and amounts) of microgliosis were observed in all injured groups; 
despite hemispheric location of the insular injury. Intriguingly, Krause and colleagues recently 
identified a co-existence of both sympathetic and parasympathetic regions in the left and right 
human IC 130. Although each hemisphere appears to exhibit a functional autonomic 
predominance (right IC = parasympathetic, left IC = sympathetic), opposing autonomic 
regions, in each IC, have been observed 130 – blurring the perceived rigidness of IC 
lateralization. Experimentally, similar observations of this autonomic variation have been 
recognized among cardiac chronotropic sites within the rat IC 219. It is therefore possible that 
damage to the right or left IC may impact both sympathetic and parasympathetic regulatory 
sites, negating distinct downstream pathological effects; however, due to the autonomic 
predominance of each hemisphere, a lateralization of behavioural deficits was still detected.  
 Furthermore, the results of this thesis only assess secondary neuroinflammation within 
remote forebrain regions; limiting current pathological conclusions. The IC is vital to the 
autonomic control of cardiovascular function, transmitting this regulatory effect on the heart 
through several brainstem regions 108–110. Neurologically, the anatomical separation of 
sympathetic and parasympathetic pathways involved with this autonomic process remains 
most apparent within the brainstem. From the IC, efferent sympathetic output predominantly 
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synapses at the RVLM, while parasympathetic outputs synapse at the DMV and/or NA; both 
located within the medulla 2. As such, the pathological representation of IC lateralization may 
be more discernable within the brainstem medulla. Interestingly, in our current rodent model, 
injured rats (IA/ET-1) exhibited significant amounts of microgliosis within the ipsilateral 
internal capsule; a fibre bundle responsible for signal transduction between the cortex and 
brainstem. Consequently, chronic display of this internal capsule microgliosis likely 
corresponds with a downstream manifestation of brainstem damage, supporting the crucial 
need for additional investigation of resulting brainstem pathology.              
4.4.4 Insular ischemic stroke and astrogliosis 
 At 28 d post-insular injury, no significant differences in astrogliosis were identified 
between experimental groups; corresponding with previous results obtained in our lab. 
Traditionally, astrocytes have been implicated as key regulators of neuroinflammation. During 
stroke, observations of acute astrogliosis remain constant, as astrocytes function to encapsulate 
the damaged region; initiating vital repair mechanisms 61,62. Presently, the specific involvement 
of astrogliosis in chronic, stroke-induced secondary neuroinflammation, remains unknown. 
Pathologically, astrogliosis has been associated with several CNS diseases 220–222. However, 
given the different origins and onsets of these injuries, the temporal and spatial changes of 
reactive astrocytes have been known to vary, depending on the disease 221. It is therefore 
possible that while acute ischemic neuroinflammatory mechanisms predominately involve 
astrogliosis, chronic secondary neuroinflammation, particularly within the white matter, 
evokes alternative neuroinflammatory responses; primarily involving microglia.     
4.5 Insular Ischemic Stroke and Remote Neurodegeneration 
In our current rodent model, increased M1 microglia activation was observed in white 
matter tracts 28 d following IC damage, displaying a chronic manifestation of white matter 
injury. As mentioned previously, past experimental studies have identified WMI as a suitable 
assay for axonal health; recognizing WMI as a histological correlate of axonal degeneration 92. 
In accordance with these claims, our current observations of enhanced microglia activation 
(WMI) within the corpus callosum and internal capsule of injured rats (IA/ET-1), would 
insinuate a co-occurrence of chronic axonal damage. 
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 Clinically, the pathological display of post-stroke white matter injury has become of 
increased concern, largely due to the suspected role of axonal damage in secondary 
neurodegeneration 92; an adverse outcome of stroke involving remote brain regions distal to 
the infarct zone 80–85. Presently, the exact mechanisms of this delayed remote pathology are 
unknown, and may vary depending on the affected structures 91. Yet, an intriguing 
commonality exists between all cases of stroke-induced secondary neurodegeneration: location 
of the remote damage is dependent on anatomical connectivity to the primary infarct 87–91, 
supporting the likely involvement of  white matter injury 92. Consequently, in observing WMI 
after IC damage, a chronic display of remote secondary neurodegeneration was expected in 
our injured rats (IA/ET-1). To affirm this anticipated outcome, total neuron counts were 
measured in five forebrain regions anatomically connected to the IC: the PFC, ACC, amygdala, 
hypothalamus and VP thalamus. Each of these areas were specifically chosen, due to their 
autonomic involvement with IC regulation of cardiovascular function. Neurodegeneration in 
any of these regions would provide valuable insight into the pathological manifestation of 
autonomic dysfunction, and associated SIHI.  
To our surprise, neuronal loss was not observed in any of the aforementioned forebrain 
regions at 28 d post-insular injury, contradicting previous experimental findings. Past studies 
involving MCAO in the rat, have consistently reported a delayed appearance of secondary 
neurodegeneration in the thalamus 87,88,90,92. Adding to this, in a recent study by Weishaupt and 
colleagues, chronic neurodegeneration and neuron cell death were observed in the retrosplenial 
cortex of the rat 28 d following the bilateral injection of ET-1 into the PFC 91. Consistently, 
this data has confirmed the experimental existence of stroke-induced secondary 
neurodegeneration, strongly opposing the results of our study. However, when analyzing this 
prior data, it became evident that our study produced a substantially smaller infarct region; 
suggesting a mechanistic impact of stroke severity on the initiation and/or perpetuation of 
remote neurodegeneration. In our current model, limiting the infarct size was considered 
necessary to produce a well-defined IC stroke, while the creation of a unilateral lesion allowed 
for the evaluation of IC lateralization. Yet, it is possible that this unilateral infarct of small 
volume may not be severe enough to produce previously described incidents of secondary 
neurodegeneration, requiring a bilateral or larger site of damage.    
To our knowledge, the correlative influence of stroke severity in remote 
neurodegeneration has yet to be investigated. However, Iizuka and colleagues have reported 
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an enhanced prominence of terminal degeneration, within the corticothalamic fibers of rats 
exhibiting a larger MCAO infarct 87; supporting this proposed mechanistic interaction. 
Recently, Weishaupt and colleagues published comparable findings to those outlined in this 
thesis, discerning an absence of secondary neurodegeneration 28 d post-ischemic stroke 217. 
Similar to our study, this experiment produced a small infarct region, injecting 1 µL of ET-1 
(10 pmol/µL), unilaterally, into the dorsomedial thalamus of the rat 217. Interestingly, while 
axonal degeneration occurred within connecting thalamocortical fibres, an accompanied 
presence of secondary degeneration in remote grey matter regions was not observed 217; 
reaffirming our results. 
In discussing this relationship of ischemic stroke and remote neurodegeneration, it is 
important to note that increased M1 microglia activation was identified in the ipsilateral VP 
thalamus of our injured rats (IA/ET-1), without the accompanying manifestation of neuronal 
loss. It is therefore possible that, although the implied presence of axonal degeneration did not 
correspond with the anticipated secondary neurodegeneration of remote brain regions; damage 
to these white matter tracts parallels a chronic disruption of signal transduction. Secondary 
activation of M1 microglia may necessitate pruning of faulty synapses, located in remote areas 
like the VP thalamus, damaged as a result of this impaired axon function 218.  
4.6 Insular Ischemic Stroke and Stroke-Induced Heart Injury 
In 1989, Cechetto and colleagues were first to experimentally investigate ischemic 
SIHI, recapitulating clinical observations of myocardial damage and dysfunction in a rodent 
model of MCAO 55. Within this study, histological analysis of collected brain tissue revealed 
an invariable inclusion of IC damage within the MCA ischemic zone 55. In seeing this, Cechetto 
proposed a mechanistic influence of IC damage in SIHI, based upon the known role of IC 
regulation in cardiovascular function. To date, various clinical and epidemiological studies 
have discerned an association between IC damage and SIHI 7,124–127; supporting Cechetto’s 
hypothesis. Most recently, Gonzalez Toledo and colleagues identified IC damage in 30.4% of 
ischemic stroke patients exhibiting atypical post-stroke ECGs; compared to a 7.3% prevalence 
in patients with normal post-stroke cardiac function 7. As such, it was anticipated that the focal 
induction of IC damage would evoke structural myocardial changes in our novel rodent model 
of insular ischemic stroke. 
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 At 28 d following IC injury, interstitial cardiac fibrosis was observed in the LA. To our 
knowledge, this is the first reported observation of stroke-induced cardiac fibrosis; as previous 
studies of SIHI have involved more acute timepoints 55,94,95,97,98,135,136. During these prior 
experiments, the structural manifestation of contraction band necrosis has consistently served 
as a histological marker of myocardial cell death 2,93,105, occurring within minutes of the 
hemorrhagic or ischemic stroke 223,224. Intriguingly, this pathology distinctly differs from 
common observations of coagulative necrosis, seen after myocardial ischemia 225; further 
supporting a mechanistic variance between traditional heart disease and SIHI. Currently, 
overactivation of the SNS, and accompanying NE toxicity, have been implicated as the cause 
of contraction band necrosis 113,226,227. Physiologically, NE is required for the regulated 
opening of myocardial Ca2+ channels, responsible for cardiac muscle contraction 113.  If 
prolonged, oversaturation of NE will stimulate cardiac muscle hypercontractivity, causing 
irreversible cell death (contraction band necrosis) 2,93. Overtime, this damaged myocardial 
tissue will begin to remodel, likely giving rise to our chronic observations of cardiac fibrosis. 
 In this thesis, fibrosis of the LA was specifically analyzed, due to the contributing role 
of LA dysfunction in AF 208,209. AF is a form of cardiac arrythmia known to increase the risk 
of stroke 5-fold 15; currently recognized as the most prevalent arrhythmia of SIHI 102. 
Clinically, these stroke-induced cases of AF have been described as brief and acute arrhythmic 
episodes, associated with a low recurrence of ischemic stroke 228,229. However, with our recent 
observations of cardiac fibrosis, a chronic development of AF, capable of more drastic 
consequences, is certainly plausible. This local infiltration of fibrotic tissue can structurally 
disrupt the subendocardium, altering the cardiac conduction system; contributing to the 
generation of persistent AF 105. Presently, it remains unknown whether the fibrotic changes 
observed in our study are severe enough to cause AF, having only been observed in 
approximately 5% of total LA area. Yet, in a clinical report by Hammermeister and 
Reichenbach, minor foci of myocytolysis were deemed capable of initiating ECG 
abnormalities 230; suggesting that less obvious cardiac lesions, like those detected in this study, 
may be sufficient in producing detrimental changes to cardiac function. Experiments within 
our lab are currently ongoing to assess the temporal progression of this fibrotic remodelling.    
Similar to observed brain pathology, the hemispheric localization of IC damage did not 
alter histological results; producing similar amounts of LA cardiac fibrosis after left or right 
insular injury. Anatomically, the LA is surrounded by four pulmonary veins (PV), which 
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together, form the PV-LA junction; a heavily innervated autonomic area, densely populated by 
both adrenergic (SNS) and cholinergic (PSNS) nerves 231. Intriguingly, these autonomic nerves 
appear co-localized at both the tissue and cellular level, with a significant proportion (30%) of 
cardiac ganglion cells displaying dual adrenocholinergic phenotypes 231. As such, with this 
lack of discrete PV-LA autonomic nerve predominance, an identical pathological display 
would be expected; regardless the type of autonomic disturbance (sympathetic or 
parasympathetic).      
4.7 Inflammation and Stroke-Induced Heart Injury   
 The contribution of inflammation to the genesis and perpetuation of SIHI has gained 
increased interest. As mentioned previously, neuroinflammation is a natural consequence of 
ischemic stroke, known to disrupt the BBB 37,64,66. Pathologically, this damage to the BBB 
enables the release of local neuroinflammatory cytokines (TNFα, IL-1β) into the periphery; 
inducing a systemic inflammatory response 37,66. Intriguingly, persistent systemic 
inflammation has been adversely linked to heart disease 187,188, as observed in chronic 
inflammatory disease (sepsis, rheumatoid arthritis) patients 232–234. We therefore sought to 
further explore the mechanistic influence of inflammation on SIHI, by correlating cerebral 
inflammation to cardiac fibrosis.  
As expected, increased microglia activation (neuroinflammation) correlated with the 
enhanced presence of LA cardiac fibrosis; likely elicited through neuroinflammatory activation 
of the systemic immune response. In the heart, including other internal organs, chronic 
exposure to systemic inflammation can impair mitochondria function, resulting in the 
unnatural accumulation of ROS 235,236. Inevitably, this elicits a cascade of oxidative damage, 
generating a local inflammatory response 235,236. Interestingly, in the recent clinical study by 
Westermann and colleagues, increased amounts of cardiac inflammatory cells positively 
correlated with enhanced cardiac fibrosis and dysfunction, in heart failure patients 237; 
validating aforementioned mechanistic predictions. Currently, ongoing studies within our lab 
are actively analyzing the local infiltration of immune cells (neutrophils, lymphocytes and 
monocytes) into cardiac tissue, following IC injury. The future correlation of these results to 
neuroinflammation and cardiac fibrosis, as well as the systemic measurement of 
proinflammatory cytokines, are crucial in elucidating the pathophysiological impact of 
inflammation on SIHI.       
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Presently, it remains unclear whether this ischemic mechanism of inflammation is 
independently capable of eliciting SIHI. Recently, Olshansky hypothesized a regulatory role 
of the ANS in myocardial cytokine production; outlining parasympathetic involvement in the 
attenuation of cardiac inflammation 114. Furthermore, overstimulation of the SNS has been 
implicated in the activation of a systemic, proinflammatory response 238 – insinuating an 
autonomic influence over associated observations of inflammation post-insular injury. It is 
therefore possible that, following stroke, ischemic-induced systemic inflammation perturbs 
cardiac tissue, evoking the infiltration of inflammatory cells into the heart. Subsequently, 
damage to the IC decreases parasympathetic tone, hindering the suppression of unwanted 
inflammation. This, coupled with chronic exposure to SNS-induced systemic inflammation, 
further exacerbates local cardiac inflammation; contributing to the observed presence of 
cardiac fibrosis. In our current model, the ischemic induction of insular stroke presumably 
causes both systemic inflammation (a direct result of the stroke) and autonomic dysfunction (a 
direct result of IC damage); making it challenging to confirm an independent effect of 
inflammation in SIHI. As such, future studies involving an alternative stroke location should 
be performed, to examine whether stroke in this alternate region, not anatomically connected 
to the IC, can produce similar levels of cardiac fibrosis as those produced in our current model.     
4.8 Limitations and Future Directions 
To date, the clinical investigation of SIHI has been challenging, due to the high 
prevalence of shared risk factors between ischemic stroke and cardiovascular disorders 2,105. 
As such, we sought to establish a rodent model of focal insular ischemic stroke; capable of 
progressing the pathophysiological understanding of SIHI, while simultaneously eliminating 
these clinically-inevitable confounding variables. Experimental development of this novel 
model has provided valuable insight into the neurological mechanisms of SIHI, confirming the 
isolated involvement of IC stroke in the development of structural cardiac damage. However, 
it is important to note that inception of this current rodent model does not exist without 
limitations; many of which can be resolved in future studies. 
Physiologically, substantial differences exist between males and females, contributing 
to sex-specific alterations in the pathophysiological manifestation, progression and recovery 
of illness and disease 239. In stroke, current epidemiological data has delineated an increased 
incidence in men, compared to women 240–242. Yet, women frequently present with more severe 
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outcomes; linked to adverse mortality rates 240–242. To our knowledge, sex-related differences 
in the underlying pathophysiology of SIHI have yet to be investigated, both clinically and 
experimentally. Unfortunately, current results presented in this study do not address this 
important, and often overlooked, phenomenon – having only used male rats. As such, future 
experimental studies of SIHI should incorporate the use of female rodents, to examine the 
likely effect of sex-specific differences involved in the mechanistic formation and perpetuation 
of stroke-induced cardiac dysfunction.                
In the present study, behavioural and pathological observations of IC damage were 
restricted to the single timepoint of 28 d post-insular injury. However, it is possible that the 
recovery of an acute pathological response may have already occurred prior to this chronic 
period, resulting in the loss of key mechanistic information. Recently, Sposato and colleagues 
reported an acute manifestation of stroke-induced cardiac arrhythmias, of which the majority 
(approximately 75%) occurred within the first three days of stroke onset 229. Additionally, 20-
60% of ischemic stroke patients exhibit an acute elevation in serum cTnT, a known biomarker 
of myocardial injury 104. Interestingly, in a recent study by Wrigley and colleagues, this 
increased presence of cTnT appeared to enhance the long-term risk for death after ischemic 
stroke 104; implying the capable manifestation of acute SIHI into chronic, deadly outcomes. It 
is therefore critical to include acute timepoints in future studies, as these early 
pathophysiological changes may provide advanced mechanistic insight into the chronic 
observations of SIHI detected in our current model.          
 Pathologically, results from this study do not take into consideration the potential 
impact of infarct size on SIHI, or its underlying mechanisms. Yet, clinically, an association 
between infarct volume and SIHI has been identified 229. In a recent study by Sposato and 
colleagues, 80% of patients diagnosed with stroke-induced AF displayed a large infarct volume 
(>15 mm), recognizing infarct size as a predictor of SIHI 229. Based upon these results, Sposato 
hypothesized that larger infarcts are associated with more severe autonomic dysregulation, 
contributing to adverse outcomes of SIHI 229. However, this has yet to be experimentally 
proven. Future comparisons of SIHI outcomes using the current rodent model, and a MCAO 
model, could enhance experimental understanding of this proposed mechanistic risk factor.      
Lastly, in this newly developed model of focal insular ischemic stroke, a direct 
assessment of cardiovascular autonomic function is absent; presenting an inherent mechanistic 
limitation. Traditionally, HRV has served as a well-established tool used to assess cardiac 
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autonomic control, in both humans and animal models 136,243,244. In the conscious rat, this 
requires the surgical implantation of a telemetric device 245. Due to the high costs associated 
with animal telemetry, initial establishment of the present model was essential to confirm 
proof-of-concept. As a next step, future studies should incorporate the use of telemetry into 
this current insular stroke model. Analysis of HRV can verify the mechanistic role of 
autonomic dysfunction in SIHI, further elucidating the pathophysiological underpinnings of 
this complex brain-heart interaction. 
In the present study, we confirmed, for the first time, the focal capability of IC ischemia 
to generate SIHI; pathologically represented as the chronic manifestation of LA cardiac 
fibrosis. At 28 d following IC injury, we identified remote microgliosis in the corpus callosum, 
ipsilateral internal capsule and ipsilateral VP thalamus. Traditionally, this chronic display of 
remote neuroinflammation has coincided with the secondary neurodegeneration of distal grey 
matter regions 92. While the anticipated neurodegeneration of autonomic forebrain regions was 
not observed in this study, significant microgliosis did occur at the internal capsule; likely 
corresponding with the downstream manifestation of autonomic brainstem damage. 
Supporting this notion, behavioural assessment of PPI displayed notable deficits following left 
IC injury, indirectly demonstrating a possible functional impairment of autonomic activity. 
Physiologically, the chronic presence of secondary neuroinflammation is also known to elicit 
a prolonged, systemic immune response 64. Based upon the recent implication of inflammation 
in myocardial fibrotic remodelling 114,187,188,210,211, we correlated microgliosis to LA cardiac 
fibrosis demonstrating, for the first time, a positive association between neuroinflammation 
and SIHI. Taken together, these downstream observations of IC ischemia further support the 
hypothesized mechanistic role, of both autonomic dysfunction and inflammation, in the 
pathophysiological cascade of SIHI (Figure 25).  
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Figure 25. Schematic summary outlining the proposed pathophysiological cascade of 
stroke-induced heart injury.   
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Section 5: CONCLUSION 
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The neurological influence of ischemic stroke in the generation of SIHI has been 
acknowledged for several years. Yet, despite decades of research, the underlying 
pathophysiology of this intricate brain-heart connection remains unknown. Clinically, it has 
been hypothesized that stroke involving the IC initiates SIHI, since the IC controls autonomic 
regulation of cardiovascular function 2,108,109. However, given the high prevalence of shared 
risk factors between ischemic stroke and cardiovascular disorders, current conclusions from 
clinical studies are largely speculative 105. We therefore sought to establish a novel rodent 
model of focal insular ischemic stroke, vitally expanding current mechanistic knowledge of 
SIHI. 
Prior to this thesis, experimental studies of SIHI have exclusively involved animal 
models of MCAO 55,135. However, use of this technique creates a large infarct region, extending 
beyond the IC 55,56,120. Consequently, the isolated association of IC ischemia with SIHI has yet 
to be confirmed. In the present study, use of ET-1 produced a focal, and much less severe, 
ischemic infarct; limiting primary ischemia to the IC region. Pathologically, this confined 
insular injury corresponded with the structural manifestation of LA cardiac fibrosis, supporting 
the overarching hypothesis of focal IC involvement in SIHI development.   
At 28 d following IC damage, rats subjected to left IC injury displayed an observable 
trend of reduced PPI, demonstrating a potential lateralization of IC autonomic function. 
Experimentally, this behavioural assessment of sensorimotor gating serves as a preliminary 
hallmark of autonomic dysfunction; indirectly supporting the mechanistic association between 
IC damage, autonomic impairment and SIHI. In correspondence with this behavioural 
phenotype, an accompanying pathology of secondary microgliosis was observed in the corpus 
callosum, ipsilateral internal capsule and ipsilateral VP thalamus, 28 d following IC ischemia. 
Traditionally, this chronic display of remote neuroinflammation has coincided with the 
secondary neurodegeneration of distal grey matter regions 92. As such, secondary neuronal loss, 
within remote forebrain regions of IC autonomic circuitry, was expected. Yet, upon 
histological examination, this anticipated chronic display of secondary neurodegeneration was 
not observed. However, significant microgliosis did occur in the ipsilateral internal capsule of 
injured rats; likely corresponding with a downstream manifestation of autonomic brainstem 
damage. Consequently, future analysis of brainstem pathology, as well as the telemetric 
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analysis of HRV, should be performed to directly affirm the mechanistic role of autonomic 
cardiovascular dysfunction in SIHI. 
In addition to autonomic dysfunction, inflammation has been implicated as a cause of 
SIHI, known to induce myocardial fibrotic remodelling 114,187,188,210,211. To further examine this 
potential pathophysiological relationship, we correlated microgliosis of the corpus callosum, 
ipsilateral internal capsule and ipsilateral VP thalamus, to LA cardiac fibrosis. At 28 d 
following IC injury, increased microgliosis consistently associated with the enhanced 
presentation of LA fibrosis; demonstrating a positive correlative relationship between these 
two variables. Presently, it remains unclear whether this ischemic mechanism of inflammation 
is independently capable of eliciting SIHI. Recently, Olshansky hypothesized a regulatory role 
of the ANS in myocardial cytokine production, outlining a parasympathetic role of cardiac 
inflammation attenuation 114. Furthermore, overstimulation of the SNS has been implicated in 
the activation of a systemic, proinflammatory response 238. It is therefore possible that, 
following stroke, ischemic-induced systemic inflammation perturbs cardiac tissue, evoking the 
infiltration of inflammatory cells into the heart. Subsequently, damage to the IC decreases 
parasympathetic tone, hindering the suppression of unwanted inflammation. This, coupled with 
chronic exposure to SNS-induced systemic inflammation, further exacerbates local cardiac 
inflammation; contributing to the observed presence of cardiac fibrosis. As such, SIHI is likely 
the synergistic result of both autonomic dysfunction and inflammation, arising from the clinical 
occurrence of insular ischemic stroke.  
To date, establishment of this insular ischemic stroke model has only just begun to 
scratch the complex, and compelling, mechanistic surface of SIHI. Currently, primary use of 
this novel model has recapitulated the clinical manifestation of SIHI after IC ischemia; creating 
a reliable experimental mold for the future investigation of this intricate disease. Presently, 
post-stroke cardiovascular complications remain a prominent cause of death 105. Yet, aside 
from the management of associated vascular risk factors, a tailored clinical plan for the 
specialized treatment of SIHI does not exist 105. Future use of this model will only enhance 
mechanistic understanding of SIHI, ultimately leading to the vital development of novel 
therapies capable of preventing these adverse cardiovascular outcomes of ischemic stroke. 
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